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Approximately 75% of patients who are newly diagnosed with bladder cancer present 
with non-muscle-invasive bladder cancer (NMIBC). NMIBC survivors have unique chronic 
burdens, including frequent recurrences, repeated surveillance cystoscopies and treatments, and 
the highest lifetime medical cost per person among all cancers. Hence, the aim of conducting this 
study was to (1) examine the prevalence of uncertainty, post-traumatic stress disorder symptoms 
(PTSS), and quality of life (QOL) in NMIBC survivors, (2) identify factors associated with 
uncertainty, PTSS, and QOL, and (3) explore the relationships among uncertainty, PTSS, and 
QOL.  
This dissertation consists of three manuscripts. The first is a systematic review of the 
literature on QOL in NMIBC survivors. The second and third manuscripts comprise the findings 
from a population-based survey study in North Carolina. The data from 376 NMIBC survivors 
were used for the analysis. The NMIBC survivors had urinary and bowel symptoms, sexual 
problems, and worries about the future, regardless of time since diagnosis. The lower cancer 
stage at diagnosis was associated with better QOL in several domains, including global health 
status, physical functioning, role functioning, social functioning, fatigue, dyspnea, and financial 
difficulties. Male survivors had better sexual function and enjoyment than females, but also 
higher discomfort with sexual intimacy and more concerns about contaminating their partners. 
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The cystectomy group had worse sexual function, more discomfort with sexual intimacy, lower 
sexual enjoyment, and more male sexual problems than the non-cystectomy group. The NMIBC 
survivors had notable burdens of cancer-related uncertainty, and higher uncertainty was 
associated with males, lower income, the lack of cure, lower cognition-ability, and higher 
cognition-general concerns. The prevalence of PTSS (28.7 %) was higher than in the general 
United States (US) adult population (10-20%). Higher PTSS were associated with younger age, 
lack of cure, more comorbidities, less social support, and more cognition-general concerns. 
Uncertainty was significantly and negatively associated with QOL, and PTSS completely 
mediated the effect of uncertainty on QOL.  
The findings of this dissertation highlight the importance of assessment and management 
of uncertainty and PTSS in the NMIBC population. Further studies are needed to better 
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CHAPTER 1: INTRODUCTION 
Background and Significance 
Bladder cancer is the sixth most common cancer in the United States (US), with more 
than 81,100 new diagnoses expected in 2018 (National Cancer Institute, 2018b; Siegel, Miller, & 
Jemal, 2018). In 2016, there were more than 765,900 bladder cancer survivors living in the US 
(Miller et al., 2016). Almost 73% of those newly diagnosed with bladder cancer are 65 years or 
older, and the median age at diagnosis is 73, which is the oldest median age of diagnosis among 
all of the cancers. Bladder cancer incidence is about three times higher in men than in women 
(National Cancer Institute, 2018b).  
Approximately 75% of newly diagnosed bladder cancer patients have non-muscle-
invasive bladder cancer (NMIBC), which is an early stage of bladder cancer with a good 
prognosis (Sanchez & Wszolek, 2015). A complete transurethral resection of bladder tumor 
(TURBT) is the most common and recommended treatment for all NMIBCs. However, there are 
risks of incomplete resection of the original tumor, implantation of tumor cells at the time of 
original resection, or new tumor occurrence (Karaoglu, van der Heijden, & Witjes, 2014). 
Almost 50% of the patients with NMIBC who do not undergo a cystectomy have a recurrence. 
Thus, regular surveillance is recommended that includes a cystoscopy every three to four months 
for two years, every six months for the second two years, and then once per year (Segal et al., 
2012; Tiu, Jenkins, & Soloway, 2014). Frequent regular surveillance cystoscopies followed by 
repeated treatment, including TURBT, intravesical chemotherapy or immunotherapy, and the 
highest lifetime treatment costs of all cancers impact on the quality of life (QOL) of people with 
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NMIBC (Sanchez & Wszolek, 2015). Nonetheless, little is known about the impact of NMIBC 
and treatment on QOL in NMIBC survivors. Most studies of QOL in bladder cancer patients 
have focused on the impact of radical cystectomy in relation to different urinary reconstruction 
methods in patients with muscle-invasive bladder cancer (MIBC) (Mohamed et al., 2016). 
Therefore, there is a critical need for more research on the unique burdens of NMIBC and the 
QOL of NMIBC survivors.  
Cancer-related Uncertainty 
After the completion of cancer treatment, cancer survivors may struggle with uncertainty 
regarding treatment side effects, recurrence, and their future health. Uncertainty in illness is 
defined as the lack of ability to determine the meaning of illness-related events (Mishel, 1988). It 
is generated when the components of illness, treatment-related stimuli, and illness-related events 
are complex, inconsistent, random, unpredictable, and/or there is a lack of information (Mishel, 
1981, 1988). Cancer-related uncertainty can be triggered by the possibility of cancer recurrence 
or the appearance of a secondary cancer after curative treatment, the presence of symptoms and 
comorbidities, side effects of treatments, and financial concerns about health-related costs (Gill 
et al., 2004; Mast, 1998). This uncertainty has a strong influence on emotional distress and QOL 
(Clayton, Mishel, & Belyea, 2006; Mast, 1998). 
Post-Traumatic Stress Disorder  
Cancer diagnosis can be considered a risk for post-traumatic stress disorder (PTSD) and 
related symptoms. Post-traumatic stress has been studied in patients with various types of cancer, 
including non-Hodgkin’s lymphoma and breast cancer (Pitman et al., 2001; Smith, Zimmerman, 
Williams, Preisser, & Clipp, 2008). Stress or trauma-related symptoms such as avoidant 
behaviors, intrusive thoughts, and heightened arousal have been reported in cancer survivors 
(Pitman et al., 2001; Smith et al., 2008). The incidence of PTSD ranges from 3-4% in recently 
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diagnosed patients to 35% in patients evaluated after treatment. The incidence of PTSD 
symptoms (PTSS, not meeting the full diagnostic criteria) is higher than that of PTSD, ranging 
from 20% in patients with early-stage cancer to 80% in those with recurrent cancer (National 
Cancer Institute, 2018a).  
Having a NMIBC diagnosis with high recurrence rates, and frequent surveillance 
cystoscopies followed by repeated treatment can be a source of uncertainty and a risk factor for 
PTSS, potentially resulting in negative effects on QOL. However, cancer-related uncertainty and 
PTSS have not been studied in the NMIBC population. Thus, we need to have a better 
understanding of NMIBC treatment-related consequences and associated factors of uncertainty, 
PTSS, and QOL in order to develop supportive care interventions for NMIBC survivors.  
Purpose 
The overall objective of this dissertation study is to explore the impact of NMIBC, cancer 
treatment, and surveillance on uncertainty, PTSS, and QOL in NMIBC survivors. In this 
dissertation, an NMIBC survivor is defined as an individual diagnosed with NMIBC (stage Ta, 
Tis, T1) from the time of diagnosis through the rest of his or her life (National Coalition for 
Cancer Survivorship, 2004). I accomplished this objective by pursuing the following specific 
aims in a cross-sectional descriptive survey of NMIBC survivors.  
Aim 1: Examine the prevalence of uncertainty, PTSS and QOL in NMIBC survivors. 
Aim 2: Identify factors (demographics, clinical characteristics, health/health behavior 
status, and psychosocial characteristics) associated with the level of uncertainty, PTSS, and QOL 




Aim 3: Explore relationships among antecedents (i.e. demographics, clinical 
characteristics, health/health behavior status, psychosocial characteristics), uncertainty, PTSS, 
and QOL in NMIBC survivors. 
Conceptual Framework 
 This dissertation is based on the conceptual model of QOL among NMIBC survivors 
(Figure 1.1), which was adapted from the QOL study on non-Hodgkin lymphoma survivors 
(Smith, Williams, Zimmer, & Zimmerman, 2011). This model is based on the Stress, Appraisal, 
and Coping Theory (Folkman, Lazarus, Gruen, & DeLongis, 1986) and the Uncertainty in Illness 
Theory (Mishel, 1988). The model has five components: demographic characteristics, 
psychosocial characteristics, stressors, psychological effects, and outcomes. Antecedents include 
demographic characteristics, psychosocial characteristics (e.g., social support, cognition), and 
stressors. Stressors include clinical characteristics (e.g., cancer diagnosis, treatment, surveillance 
cystoscopy) and general health and health-behavior status (e.g., other cancer, comorbidities, 
smoking). Demographic characteristics and psychosocial resources are related to the stressors. 
The three sets of antecedent variables (demographics, psychosocial characteristics, and stressors) 
can directly or indirectly influence the experience of uncertainty and PTSS. The outcome of the 
model is QOL, which is affected by the experience of uncertainty and PTSS. In addition, 
demographics, psychosocial characteristics, and stressors can directly or indirectly affect QOL 
via the experience of uncertainty and PTSS. 
Outline of Dissertation 
Chapter 1 is an introduction of the dissertation. The study background, theoretical 
framework, and aims of the study have been presented. Chapters 2, 3, and 4 are three 
manuscripts that correspond to each specified aim of the study. Chapter 2 (Manuscript 1), titled 
“Quality of Life in Non-Muscle-Invasive Bladder Cancer Survivors: A Systematic Review,” is a 
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literature review of NMIBC survivorship and QOL. A comprehensive synthesis of the literature 
is provided. The aim of this review is to explore existing studies in which the impact of NMIBC 
diagnosis, treatment, and surveillance on QOL in NMIBC survivors was investigated. Chapter 3 
(Manuscript 2), titled “Quality of Life among Non-Muscle-Invasive Bladder Cancer Survivors: 
A Population-Based Study,” describes the level of QOL and examines the impact of sex, cancer 
stage, time since diagnosis, and treatment on QOL in NMIBC survivors. Chapter 4, (Manuscript 
3), titled “Relationships among Uncertainty, Post-Traumatic Stress Disorder Symptoms, and 
Quality of Life in Non-Muscle-Invasive Bladder Cancer Survivors,” comprises a report 
onpresents: 1) the prevalence of uncertainty and PTSS; 2) the effects of antecedents (i.e. 
demographics, clinical characteristics, health/health behavior status, psychosocial characteristics) 
on QOL; and 3) the relationships among uncertainty, PTSS, and QOL in NMIBC survivors. 
Structural equation modeling (SEM) was used to test a theoretical model of QOL among NMIBC 
survivors. Chapter 5 is a synthesis of the three manuscripts’ findings. In this chapter, the 




Figure 1.1. The conceptual model of QOL among NMIBC survivors [adapted from Smith 
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CHAPTER 2: QUALITY OF LIFE IN NON-MUSCLE-INVASIVE BLADDER CANCER 
SURVIVORS: A SYSTEMATIC REVIEW 
Introduction 
Bladder cancer is the sixth most common cancer, and the fourth most common cancer 
among men in the United States (US) (Siegel, Miller, & Jemal, 2017). More than 79,000 people 
are diagnosed with bladder cancer every year. As of 2014, an estimated 696,440 people were 
living with bladder cancer in the US (National Cancer Institute, 2017; Surveillance, 
Epidemiology, and End Results Program, 2017). Among all cancers, bladder cancer carries the 
greatest lifetime treatment cost for patients from diagnosis to death (Botteman, Pashos, Redaelli, 
Laskin, & Hauser, 2003; Yeung, Dinh, & Lee, 2014). In 2010, bladder cancer was responsible 
for almost 4 billion dollars in medical costs (Mossanen & Gore, 2014).  
Bladder cancer is divided into two major categories based on the level of invasion of the 
muscularis propria in the bladder wall: non-muscle-invasive bladder cancer (NMIBC) (stage 
Ta/CIS –T1) and muscle-invasive bladder cancer (MIBC) (stage T2-T4a). Treatments for bladder 
cancer differ by the stage of cancer; MIBC is generally treated by cystectomy and urinary tract 
reconstruction with or without systemic chemotherapy and/or radiation whereas NMIBC is 
typically treated by transurethral resection of a bladder tumor (TURBT) with or without 
intravesical chemotherapy or immunotherapy (Griffiths, 2013). TURBT with intravesical 
therapy, which is a standard therapy for patients with intermediate or high-risk NMIBC, is 
usually associated with side effects ranging from local urinary symptoms such as dysuria, 
frequency, and urgency to a severe inflammatory response (Chade, Shariat, & Dalbagni, 2009). 
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Approximately 75% of bladder cancer patients have NMIBC at the time of diagnosis 
(Sanchez & Wszolek, 2015). In addition to the high incidence rate of NMIBC, almost 60% of 
NMIBC patients have a recurrent cancer (Sylvester et al., 2006). Even though a complete 
TURBT is a recommended treatment for all NMIBC, there are risks of incomplete resection of 
the original tumor, implantation of tumor cells at the time of original resection, or new tumor 
occurrence (Karaoglu, van der Heijden, & Witjes, 2014). Thus, regular surveillance cystoscopy 
of the bladder is routinely performed for NMIBC patients (Tiu, Jenkins, & Soloway, 2014). 
Also, patients with recurrent NMIBC receive repeated TURBTs and intravesical instillations of 
immunotherapy or chemotherapy (Nord et al., 2010).  
Despite NMIBC patients representing 75% of bladder cancer incidents and having the 
high frequency of recurrence followed by repeated treatment and every three-month surveillance 
cystoscopies, little is known about disease- and treatment-related consequences on the quality of 
life (QOL) of patients with NMIBC. Most studies of QOL in bladder cancer patients have 
focused on the impact of radical cystectomy with different urinary reconstruction methods in 
patients with MIBC (Mohamed et al., 2016). Therefore, given the high prevalence of NMIBC 
and the unique chronic burden of invasive surveillance and frequent recurrences necessitating 
repeated rounds of invasive treatment, a better understanding of health status and QOL for 
NMIBC group is needed. The purpose of the current literature review is to systematically 







Following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA) guidelines (Moher, Liberati, Tetzlaff, Altman, & The PRISMA Group, 2009), the 
PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and PsycINFO 
databases were searched from January 1, 2005 to March 31, 2017 to identify pertinent studies 
investigating QOL in NMIBC survivors. The following search terms, developed in consultation 
with a health sciences librarian, were used in combination: bladder cancer or bladder neoplasm 
or bladder tumor or bladder carcinoma and QOL (Table 2.1). Searches were limited to human 
studies published in English. 
Inclusion and Exclusion Criteria 
The reports had to meet the following inclusion criteria: (a) participants of the study 
were NMIBC survivors, defined as individual diagnosed with non-muscle-invasive bladder 
cancer (stage Ta, Tis, T1), “from the time of diagnosis, through the balance of his or her life” as 
suggested by the National Coalition for Cancer Survivorship (2004, p.1); (b) outcomes included 
QOL; (c) studies were published as original articles in peer-reviewed journals; and (d) articles 
were published in English. If the study participants included both NMIBC and MIBC and the 
percent of their sample with NMIBC was reported, the study was included. 
A report was excluded if it was: (a) an evaluation of medical treatment outcomes (e.g., 
survival rate, complications), (b) not a primary research report (e.g., editorials, opinions, 
seminars, clinical guidelines, case studies, and literature or systematic reviews), (c) an abstract, 




All retrieved articles from the search, after removing duplicates, were screened by title 
and abstract first. Then, the full-text articles were screened further for eligibility. After the full-
text screening, studies that met the inclusion criteria were included in this review study. 
Data Extraction 
Data were extracted from the eligible studies using a standard matrix which included 
study characteristics (authors, publication year, study design, research purpose, 
inclusion/exclusion criteria, study duration, and sampling), participant characteristics (age, 
gender, and sample size), measurement tools, data collection occasions, and findings/outcomes 
(overall QOL, physical QOL, psychological QOL, sexual QOL, and other issues). The overall 
quality of the eligible studies was evaluated using the Mixed Methods Appraisal Tool (MMAT) 
for systematic reviews including quantitative, qualitative, and mixed methods studies (Pluye et 
al., 2011). Using the MMAT scoring metrics, the overall quality score is presented using 
asterisks (*), with more asterisks indicates better quality: 0 (none), * (25%), ** (50%), *** 
(75%), and **** (100%). 
Findings 
Search Results 
A flowchart of the study selection process is shown in Figure 2.1. Initially, 546 articles 
were retrieved: 462 from PubMed, 64 from CINAHL, and 20 from PsycINFO. After excluding 
63 duplicates, the primary search resulted in 483 articles. Preliminary screening yielded 68 
potentially appropriate studies based on title, abstract, or both. Of the 68 studies, 53 studies were 
excluded by the full-text screening, because these articles: (a) did not present data separately for 
patients with NMIBC (n=42); (b) did not have NMIBC participants (n=7); (c) were not primary 
research reports (n=2); (d) did not measure QOL as an outcome variable (n=1); or (e) was a 
measurement development study (n=1).  
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General Characteristics of Included Studies 
A total of 15 studies were identified for inclusion in this review study: characteristics of each 
study are provided in Table 2.2. Study designs were cross-sectional (6 articles), prospective 
longitudinal (3 articles), prospective longitudinal randomized (2 articles), longitudinal 
randomized control trial (2 articles), prospective cohort (1 article), and mixed-methods (1 
article). Study participants had NMIBC only in 11 studies while data for NMIBC were extracted 
from 4 studies that included both NMIBC and MIBC patients. Most studies (13 articles) were 
convenience samples from referral centers, whereas only two articles were population-based 
samples (Allareddy, Kennedy, West, & Konety, 2006; Fung et al., 2014). Sample size ranged 
from 30 to 1476. Average age of participants in the studies ranged from 60.4 to 76.4 years. 
Available date of original data collection ranged from 1998 to 2013.  
QOL Instruments 
The studies used a variety of QOL instruments and interview format (Table 2.2). Most 
studies used generic instruments or combinations with disease/symptom-specific instruments.  
The QOL instruments used in the studies can be categorized into three main groups: 
Generic/cancer-specific QOL instruments, disease-specific instruments, and symptom-specific 
instruments.  
Generic/cancer-specific QOL instruments. Two generic (Medical Outcomes Study 36-
item Short Form (SF-36) and Veterans RAND 12-item health survey (VR-12)) and two cancer-
specific QOL instruments (European Organization for Research and Treatment of Cancer 
Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) and Functional Assessment of 
Cancer Therapy-General (FACT-G)) were identified. SF-36 was used in 3 articles, VR-12 in 1 
article, EORTC QLQ-C30 in 5 articles, and FACT-G in 1 article. One study used VAS (Visual 
Analogue Scale) to assess general state of health.  
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Disease-specific QOL instruments. Three bladder cancer disease-specific instruments 
were identified: FACT-Bladder Cancer (FACT-BL), Bladder Cancer Index (BCI), and EORTC 
QLQ-Bladder Cancer Superficial 24 (EORTC QLQ-BLS24; currently, name changed to 
EORTC-QLQ NMIBC24). FACT-BL was used in 1 article, BCI was used in 2 articles, and 
EORTC QLQ-BLS24 was used in 2 articles. 
Symptom-specific QOL instruments. Physical symptoms were measured with several 
instruments; CTCAE (Common Terminology Criteria for Adverse Events), CLSS (Core Lower 
Urinary Tract Symptom Score), I-PSS (International Prostate Symptom Score), and NRS 
(Numeric rating scale) were used only once each. NRS was used to assess pain perception. 
Psychological symptoms were assessed with BSI-18 (Brief Symptom Index-18), IIRS 
(Illness intrusive rating scale), and HADS (Hospital Anxiety and Depression Scale). Each of the 
scales was used once in the studies. 
Sexual issues are important aspects of the overall QOL for bladder cancer survivors, and 
were measured using dimension-specific instruments. Sexual satisfaction questionnaire and IIEF-
5 (International Index of Erectile Function) were used once; however, these questionnaires were 
not specifically developed for NMIBC. One study (Van der Aa et al., 2009) focusing on sexual 
function in NMIBC used only sexual function questions from the EORTC QLQ-BLS24.  
Impact of NMIBC on QOL  
The research findings of the included studies are detailed in Table 2.3.  
 QOL of NMIBC compared with MIBC or with the general population. In a cross-
sectional mailed survey with 259 long-term survivors of bladder cancer (mean time since 
diagnosis 99.8 months; minimum time since diagnosis 45 months), QOL was compared between 
those who had radical cystectomy and those with an intact bladder (Allareddy et al., 2006). The 
study had mixed cancer types (NMIBC and MIBC). While NMIBC patients were included in 
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both radical cystectomy and intact bladder groups, they had mostly an intact bladder: 66.1% of 
177 patients with intact bladder were stage Tis, and 29.9% of those were localized cancer to site 
of origin; 8.5% of 82 patients with radical cystectomy were stage Tis, 74.4% of those were 
localized cancer to site of origin, and 13.4% of those were regional cancer (direct extension to 
adjacent organs or tissue only). In the long-term survivors, general QOL scores did not differ 
between the radical cystectomy and the intact bladder groups nor did they vary by time since 
diagnosis. In the intact bladder group, the older (>80 years) had significantly worse QOL than 
the youngest (£70 years) survivors. But within the radical cystectomy group, QOL did not differ 
across age groups. Another cross-sectional mailed survey comparing intact bladder and 
cystectomy groups on shorter-term survivors (median times since diagnosis 2.9 years, range = 
0.2 - 9.8 years) had different findings on QOL (Gilbert et al., 2007). The study also included 
mixed cancer types: 70.1% of 127 intact bladder patients and 41.0% of 188 cystectomy patients 
had NMIBC; the remainder had MIBC. The cystectomy group had lower scores (worse QOL) in 
all function and bother subdomains than the intact bladder group.  
Singer et al. (2013) compared the QOL in 812 bladder cancer patients (NMIBC and 
MIBC) with that of 2037 people in the general population. The mean time since diagnosis was 
24 months. Both NMIBC and MIBC patients had lower QOL in all domains for function and 
symptoms than the general population. After adjusting for age and sex, the largest differences 
between patients and the general population were observed in fatigue, social functioning, and 
role functioning. However, there were no differences in QOL between NMIBC and MIBC after 
adjusting for the effects of age, sex, treatment, and time since surgery. The QOL increased with 
time in all patient groups (p<0.01). Another cross-sectional study assessed the impact of bladder 
cancer (NMIBC and MIBC) on QOL in 1476 older patients and compared QOL in a pre-
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diagnosis sample with a post-diagnosis sample (Fung et al., 2014). In NMIBC patients, both 
physical and mental QOL was higher pre-diagnosis; with physical scores remaining significantly 
lowered for more than 10 years post-diagnosis, and mental scores returning to baseline levels 
around 5 years post-diagnosis. In MIBC patients, the physical scores post-diagnosis (for up to 10 
years) were significantly lower than pre-diagnosis, but the mental scores were not significantly 
different between pre- and post-diagnoses.  
Physical QOL. Patients with NMIBC experience physical problems related to cancer, 
treatment, and surveillance procedures. A prospective longitudinal study examined the impact of 
TURBT, the standard treatment for NMIBC, on QOL in NMIBC patients (Yoshimura et al., 
2005). The physical functioning of patients was lowest at the third TURBT, but returned to 
normal level if TURBT was repeated four or more times. 
One longitudinal randomized study compared QOL between NMIBC patients who 
received adjuvant intravesical gemcitabine and those who received bacillus Calmette -Guérin 
(BCG) (Gontero et al., 2013). Although the gemcitabine group reported better QOL in urinary 
symptom distress and intravesical treatment problems than the BCG group on univariate 
analyses, there were no significant differences between the gemcitabine and BCG groups in all 
QOL dimensions on multivariate analyses after adjusting for all effects that were significantly 
different on univariate analyses. Also, no significant changes were detected over their 
intravesical instillation treatment periods in QOL except for physical functioning, which 
decreased significantly over time in both groups. Another randomized controlled trial compared 
the maintenance therapy and the observation groups in NMIBC patients having BCG treatment 
(Koga et al., 2010). During the induction therapy, more than 70% of patients reported urination-
related adverse drug reactions such as painful urination (82.2%), urinary frequency (82.2%), and 
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gross hematuria (72.2%). However, the BCG induction therapy as well as the maintenance 
therapy did not significantly deteriorate the QOL scores over time. In contrast, Wei, Li, Liang, 
and Jianbo (2014) found significant decreases in QOL (global health status and social 
functioning) and significant increases in symptoms (pain, diarrhea, and frequencies) six weeks 
after intravesical treatment compared to baseline. The lower urinary tract symptoms were 
significantly associated with global health status (negative association) and pain (positive 
association). In one study, bowel problems, nausea, and vomiting were associated with 
conservative therapy (chemotherapy, radiotherapy) (Singer et al., 2013). However, bowel and 
urinary problems were significantly higher among the bladder cancer patients with cystectomy 
than those with an intact bladder (Gilbert et al., 2007). In a prospective cohort study, urinary 
symptoms significantly improved over time from diagnosis to one-year follow-up (Schmidt et 
al., 2015). 
Psychological QOL. The diagnosis of bladder cancer and its treatment may be 
associated with psychological problems. Singer et al. (2013) demonstrated that bladder cancer 
patients had decreased emotional functioning when compared with the general population. In one 
prospective cohort study, the mental health of NMIBC patients was significantly worse than the 
US general population both at the time of cancer diagnosis and at 6-month follow-up (Schmidt et 
al., 2015). Fung et al. (2014) also found that mental health was significantly worse after NMIBC 
diagnosis than before.  
 Mental health scores deteriorated most severely at the first TURBT, and returned to 
normal level with repeated TURBT (Yoshimura et al., 2005). In addition, role-emotional (role 
limitations because of emotional problems) and social function were at the lowest level (worst 
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QOL) at the third TURBT, and gradually improved thereafter. Intravesical treatment also 
decreased social functioning significantly and increased financial difficulties (Wei et al., 2014).  
 Sexual health. Kowalkowski et al. (2014) showed that NMIBC survivors experienced 
erectile difficulty (60% of sexually active male respondents), ejaculation problem (43.1% of 
sexually active males), and vaginal dryness (62.5% of sexually active females). More males were 
sexually active than females, and survivors who had no interest in sex were closer to time of 
initial diagnosis and treatment (mean: 16.7 months) than those who reported at least some 
interest in sex (median: 25.4 months). Some NMIBC survivors reported concerns about 
contaminating their partner with treatment agents and noted its negative impact on their 
relationships (Kowalkowski et al., 2014; Van der Aa et al., 2009). In a prospective longitudinal 
study assessing the effect of BCG on erectile function, all the male patients had impaired sexual 
function during intravesical treatment (Sighinolfi et al., 2007). The quality of penile erections 
decreased within 36-48 hours after the instillation, then improved one month after the last 
instillation. Another study conducted among NMIBC patients who received TURBT 
with/without intravesical instillation treatment showed deterioration in sexual function over time 
during the first year of disease management (Schmidt et al., 2015). Bladder cancer survivors who 
underwent radical cystectomy had worse sexual function than those with an intact bladder 
(Allareddy et al., 2006; Gilbert et al., 2007).  
Discussion 
This paper reviewed the studies assessing QOL in non-muscle-invasive bladder cancer 
survivors with foci on QOL measures and impact of NMIBC diagnosis and treatment. NMIBC 
survivors had impaired physical, psychological, and social QOL compared to the general 
population. Assessing and understanding the symptom experience and QOL of NMIBC survivors 
are imperative to determine which symptoms are most problematic at which points in the 
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continuum of initial diagnosis and treatment, through survivorship, to inform development of 
potential intervention strategies. Over the last 13 years, there were only a few studies (n=11) that 
have focused on QOL in NMIBC (75% of bladder cancer). Most of the studies were conducted 
in MIBC (25% of bladder cancer) evaluating the impact of various treatment options on QOL 
(49 out of 68 full-text articles reviewed). While a subset of patients with NMIBC undergo 
cystectomy, most of the studies reporting on QOL after cystectomy did not separate participants 
by MIBC and NMIBC, and therefore only a few studies (4 out of 46) were included in this 
focused review of NMIBC QOL studies.  
Cancer diagnosis and its treatment may significantly affect QOL and activities of daily 
living. Bladder cancer survivors had lower QOL in all aspects than the general population 
(Singer et al., 2013). The QOL of NMIBC and MIBC were not different in the short-term (Singer 
et al., 2013), but one long-term study showed that NMIBC survivors had lower physical health 
(for more than 10 years) and mental health (for five years) than at pre-diagnosis, whereas MIBC 
survivors had only lower physical health (for up to 10 years) (Fung et al., 2014). In addition, 
cystectomy impaired QOL in all aspects compared to those with an intact bladder in short-term 
(Gilbert et al. 2007). Over the long-term, however, there were no significant differences between 
cystectomy and intact bladder groups (Allareddy et al., 2006).  
TURBT and intravesical chemo/immunotherapy are the typical treatments for NMIBC, 
and due to the high recurrence rate of NMIBC, are often repetitively experienced over time in 
NMIBC survivorship. Repeated TURBT and intravesical instillation treatments decreased 
physical function and caused pain and bowel and urinary problems compared to single treatment 
(Gontero et al., 2013; Koga et al., 2010; Wei et al., 2014; Yoshimura et al., 2005). In another 
study, the urinary symptoms improved over time in NMIBC patients undergoing TURBT with or 
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without intravesical therapy (Schmidt et al., 2015). The treatments for NMIBC also were 
associated with deteriorated mental health and social functioning (Fung et al, 2014; Wei et al., 
2014; Yoshimura et al., 2005). Mental health was impaired most severely at the first TURBT, 
and physical function, role emotional, and social function at the third TURBT. These domains 
returned to normal level with repeated TURBT (Yoshimura et al., 2005). These results suggest 
potential unmet needs in expectation setting and self-management for patients in the first few 
TURBT and intravesical instillation treatments. 
The majority of the reviewed studies were mainly focused on physical symptoms and 
functional QOL, and less so on psychological QOL and social QOL. Although generic 
instruments used in the reviewed studies (9 out of 15 studies) included all physical symptoms, 
functional, psychological, and social domains/items, bladder cancer-specific and symptom-
specific instruments used in the reviewed studies (8 out of 15 studies) with/without generic 
instrument focused on urinary, bowel, and sexual problem/function domains. Only two studies 
used psychological symptom-specific instruments. Although bladder cancer has the highest 
medical cost per patient, from diagnosis to death among all cancer types, to our knowledge no 
attempt has been made to conduct a study that focused on psychological and social QOL related 
to the financial burden of diagnosis, treatment, and surveillance of bladder cancer.    
Urinary and bowel problems, and sexual function are the most prominent physical 
symptoms of concern to NMIBC survivors. Although these symptoms and concerns are specific 
to bladder cancer survivors, four studies used only generic QOL instruments without bladder 
cancer-specific QOL or symptom instruments. Studies of QOL in bladder cancer survivors have 
been hampered by the lack of a validated, reliable QOL instruments that individually addresses 
the domains most likely affected by bladder cancer and its treatment (Gilbert et al., 2010; Wright 
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& Porter, 2007). Among the bladder cancer disease-specific QOL instruments, only bladder 
cancer index (BCI) and Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index 
(FACT-VCI) have been validated to date (Mohamed et al., 2016). In addition, the BCI and 
FACT-VCI are not NMIBC specific QOL instruments: BCI was developed for bladder cancer 
and FACT-VCI was developed for solely cystectomy. EORTC QLQ-BLS24 and FACT-BL 
instruments have not been validated in patients with bladder cancer, and studies for validity and 
reliability with these instruments are ongoing. Thus, much of the existing literature has been 
limited by non-validated bladder cancer disease-specific instruments. 
Limitations 
The current review has several limitations. First, the search was restricted to the 
English-language studies since 2005 from three electronic databases. Including non-English 
studies may add to the knowledge about symptoms and QOL in NMIBC survivors. Second, the 
search revealed only a small number (n=11) of studies conducted focusing on NMIBC, whereas 
there were more studies (n=58) that focused on MIBC patients. Because the findings were drawn 
from limited NMIBC-specific studies, this review may not be generalizable for all NMIBC 
survivors. Third, studies of poor quality were included in the current review due to low number 
of NMIBC studies. Fourth, the pooled information was difficult to evaluate due to differences in 
design, patient groups (stages, age, time since diagnosis, treatments, etc.), measurement methods, 
and QOL instruments. 
Implications for Future Research 
This review increases our knowledge about commonly reported symptoms and concerns 
experienced by NMIBC survivors. NMIBC survivors had impaired physical, psychological, and 
social QOL compared to the general population. Oncology healthcare providers are in the critical 
position for assessing and managing symptoms and concerns with the aim of improving patients’ 
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QOL. As important, this review identifies gaps in the literature on other aspects of QOL in this 
population. Despite NMIBC survivors experiencing impaired mental health and social function 
for years, only a few studies focus on psychological and social QOL and on interventions to 
improve them. In the future, more studies should address the psychological and social QOL in 
NMIBC survivors. In addition, with increasing recognition of the financial burdens of bladder 
cancer care, the paucity of existing work in this population warrants additional study. Also, the 
ongoing development and validation of bladder cancer-specific QOL instruments warrant further 
support and research to improve the quality of evidence about QOL in NMIBC patients. 
Conclusion 
 It is important to note that the reviewed QOL studies in NMIBC survivors represent the 
minority of QOL studies in bladder cancer, despite the majority (more than 75%) of newly 
diagnosed patients being in this group. While numbers were limited, the studies in this review 
describe a significant QOL burden across multiple domains in the large and growing population 
of patients with NMIBC. These data suggest further work is warranted to better understand 
potential opportunities to mitigate the burden. This work should include longitudinal studies 
measuring the long-term survivor’s QOL, the use of population-based samples, the use of 
qualitative or mixed methods, the use of validated QOL instruments, and the use of theoretical or 
conceptual frameworks in this population. 
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Table 2.1. Search Terms 
Database Search terms 
PubMed 
("Urinary Bladder Neoplasms"[Mesh] OR “Bladder Neoplasm” OR 
“Bladder Neoplasms” OR "Bladder cancer" OR “Bladder cancers” OR 
“Bladder tumor” OR “Bladder tumors” OR “Bladder carcinoma” OR 
“Bladder malignancy” OR “Bladder malignancies”) AND ("Quality of 
Life"[Mesh] OR "Quality of Life" OR QoL) 
Limiters - Publication date from 2005/01/01 to 2017/03/31; Humans; 
English 
CINAHL 
(MH “Bladder neoplasms” OR "bladder neoplasm*" OR "Bladder cancer*" 
OR “Bladder tumor*” OR “Bladder carcinoma” OR “Bladder malignanc*”) 
AND (MH "Quality of life" OR "Quality of life" OR QoL) 
Limiters - Published Date: 20050101-20170331; English Language; 
Human 
PsycINFO 
("Bladder neoplasm*" OR "Bladder cancer") AND "Quality of life" 






Table 2.2. Summary of Characteristics of Studies Included in the Review 
First author 
(year) 
Study design Number of Participant Age 
(years) 
Measurements tools Measurement   
time and occasions 
Study 
methodological 
quality score NMlBC MIBC 
Abbona 
(2007) 
Cross-sectional  63 N/A Mean  
67 
Author-designed 
questionnaire (52 items) 
At least 12 months after 1st 








































SF-36 (or VR-12) 
 






























T0: Before the start of 
instillations 
T1: After the induction cycle 
T2: The end of the 













1) Before induction Tx  
2) After thr 5th induction Tx  
3) 4-weeks after the 
completion of induction Tx 


































100 N/A Mean 69 Sexual Satisfaction 
Questionnaire,  
HADS, 
NRS (for pain perception) 
1) Before cystoscopy 
(baseline) 






244 N/A Mean 69.9 SF-36, 
BCI 
1) Baseline (during 
diagnostic process) 
2) 6-month follow up 






30 N/A Mean 60.4 
(Range: 
 49-65) 
IIEF-5 (Italian version), 
I-PSS (Italian version) 
1) 3rd or 4th session of Tx 











van der Aa 
(2009) 
Cross-sectional 142 N/A Sexually 
inactive: 69 
active: 65  
VAS (for general state of 
health), 
EORTC QLQ-BLS24 (only 
8 questions on sexual 














1) Before starting the 
intravesical Tx 













CTCAE version 3.0 
 
1) Before BCG instillation 
2) Within 2 weeks after the 
completion or 









1st TUR: 93 
2nd TUR: 34 
3rd TUR: 17 
4th or more 
TUR: 34 
N/A 1st TUR: 66.3 
2nd TUR: 65.1 
3rd TUR: 70.7 
4th or more 
TUR: 69.8 
SF-36 (Japanese version 
2.0)  
Before each TUR 
1) 1st TUR, 
2) 2nd TUR 
3) 3rd TUR 
4) 4th or more TUR 
*** 
Note. BCG = Bacillus Calmette–Guérin; BCI = Bladder Cancer Index; BSI-18 = Brief Symptom Index-18; CLSS = Core Lower Urinary Tract Symptom Score; 
CTCAE = Common Terminology Criteria for Adverse Events; Dx = Diagnosis; EORTC QLQ-BLS24 = European Organization for Research and Treatment of 
Cancer Quality of Life Core Questionnaire-Bladder Cancer Superficial 24; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer 





Therapy-General; HADS = Hospital Anxiety and Depression Scale; IIEF-5 = International Index of Erectile Function; IIRS = Illness Intrusiveness Rating Scale; 
I-PSS = International Prostate Symptom Score; MG = maintenance group; MIBC = Muscle-invasive bladder cancer; N/A= Not available; NMIBC = Non-
muscle-invasive bladder cancer; NRS = Numeric rating scale; OG = observation group; RCT = Randomized Control Trial; SF-36 = Medical Outcomes Study 36-






Table 2.3. Findings of Studies Included in the Review 
First author 
(year) Overall QOL Physical QOL Psychological QOL Sexual QOL Other issues 
Abbona 
(2007) 
  Intravesical therapy 
altered self-esteem (38% 
of respondents) 
Intravesical therapy altered 
sexual activity/life in the 
couple (46% of 
respondents) 
Intravesical therapy altered 
working activity/relations 
(43% of respondents) 
Allareddy 
(2006) 
No statistically significant 
differences in overall 
QOL: between radical 
cystectomy and bladder 
intact groups; and 
between the time since 
diagnosis groups. 
QOL for bladder intact 
patients were 
significantly worse in the 
older (age >80 years) 
than the younger (age 
£70 years).  
  Patients undergoing radical 
cystectomy had worse 
sexual function scores than 
bladder intact patients. 





 Statistically significant 
differences (-1.9, 
p<0.01) in physical 
component summary 





p=0.01) in mental 
component summary 
scores between the pre- 
and post-diagnosis 
groups 
 Education level, comorbid 
medical condition, 
impaired ADL were 
significantly associated 
with differences in 
physical and mental 
scores between the pre- 
and post-diagnosis 
groups. 
More advanced bladder 
cancer, older age at 
diagnosis, and lower 
household income were 
significantly associated 
with differences in 
physical scores between 











showed relatively lower 
scores compared with 
intact bladder groups in all 
of the function and bother 
subdomains. 
Urinary function, urinary 
bother, and bowel bother 
scores were significantly 
lower in the cystectomy 
with neobladder than the 
intact bladder. 
 Sexual function and sexual 
bother scores were 
significantly lower among 
the cystectomy compared 




No significant differences 
between Gemcitabine and 
BCG groups in all QOL 
dimensions on multivariate 
analysis. 
No significant changes 
over time in QOL domains 
for both groups except for 
physical functioning. 
General worsening of the 
physical capacitates of 
the patients undergoing 
intravesical instillations, 
regardless of the drug 
used. 
Emotional functioning in 
the Gemcitabine group 
was improved over time, 





QOL was not significantly 
different between after 
induction therapy and after 
maintenance therapy. 
During induction therapy, 
more than 70% of 
patients experienced 
urination-related adverse 
drug reactions such as 
pain on urination 
(82.2%), urinary 
frequency (82.2%), and 
gross hematuria (72.2%). 




 Maintenance therapy had 
fewer adverse drug 




   Participants reported sexual 
dysfunction (50%), 
sexual inactivity (38.8%).  
Sexual active participants 
reported erectile difficulties 
(60%), ejaculation problem 
(43.1%), vaginal dryness 
(62.5%), and worry about 
contaminating partner with 
treatment agents (23.2%). 
More women were 
significantly inactive than 
men. 
Participants reported 







(year) Overall QOL Physical QOL Psychological QOL Sexual QOL Other issues 
Between no interested in 
sex (16.7 months) and at 
least some interest in sex 
(25.4 months) groups were 
significantly different in 
time since diagnosis. 
Krajewski 
(2017) 
  Anxiety was significantly 
decreased after flexible 
cystoscopy.  
Sexual satisfaction was 
significantly decreased after 
rigid cystoscopy. 
The flexible cystoscopy had 
three times lower pain than 
the rigid cystoscopy. 
Schmidt 
(2015) 
 Urinary domain 
improved significantly 
from diagnosis to 12-
month evaluation. 
Mental health was 
significantly worse than 
SF-36 reference norms at 
diagnosis and 6-month 
evaluation. 
Sexual function showed 
deterioration from diagnosis 
to 12-month evaluation. 
Sexual summary score 
changes from baseline to 
12-month was significantly 
different by tumor stage 
(patients diagnosed at stage 
0a improved, whereas those 




   All the patients reported 
impaired sexual function 
during BCG treatment: the 
main decrease in erection 
was distinct within 36-48 
hour after the instillation. 
I-PSS score above 7 during 
the treatment, baseline 
erectile function, and 
hyperpyrexia were 
independent prognostic 




Bladder cancer patients 
had significantly low QOL 
in all domains compared to 
the general population. 
NMIBC and MIBC 
patients had decreased 
physical functioning 
compared to the general 
population. 
NMIBC and MIBC 
patients had decreased 
emotional functioning 
compared to the general 
population 
 Social and role function and 
fatigue were the largest 
differences between 
patients and the general 
population.  
 
van der Aa 
(2009) 
Sexually active patients 
had significantly higher 
scores in general state of 
health than sexually 
inactive patients.  
  61% of patients under 
surveillance for bladder 
cancer were sexually active: 
66% of male, 46% of 
female. 
Aging had a negative effect 






(year) Overall QOL Physical QOL Psychological QOL Sexual QOL Other issues 
Patients had sexual 
dysfunction (54%) and 





treatment, global health 
status and social 
functioning decreased 
significantly. 




  Financial difficulties 
increased after intravesical 
treatment. The scores of 
global health status and 
pain were significantly 
associated with the lower 
urinary tract symptoms. 
Yokomizo 
(2016) 
Global QOL was 
significantly better in the 
40mg group than in the 
80mg group. 
   Fever, pain, financial 
problems and role function 
were significantly better in 
the 40mg group than in the 
80mg group.  
Yoshimura 
(2005) 
The general health 
perception was the severest 
impaired throughout 
follow-up. 
Physical function was the 
most severely impaired at 
the third TUR, and 
returned to normal level 
if TUR was repeated four 
or more times. 
Mental health was 
impaired most severely at 
the first TUR, and 
gradually returned to 
normal as TUR was 
repeated. 
 Role-emotional and social 
function were the most 
severely impaired at the 
third TUR, and returned to 
normal level if TUR was 
repeated four or more 
times. 
Note. ADL = Activities of Daily Living; BCG = bacillus Calmette-Guérin; I-PSS = International Prostate Symptom Score; SF-36 = Medical Outcomes Study 36-










 Abbona, A., Morabito, F., Rossi, R., Billia, M., Liberale, F., & Ferrando, U. (2007). Quality of 
life in patients undergone oncopreventive intravesical treatment for superficial bladder 
cancer. Archivio Italiano di Urologia, Andrologia, 79(4), 143-146.  
Allareddy, V., Kennedy, J., West, M. M., & Konety, B. R. (2006). Quality of life in long-term 
survivors of bladder cancer. Cancer, 106, 2355-2362. doi: 10.1002/cncr.21896  
Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B., & Hauser, R. (2003). The health 
economics of bladder cancer: a comprehensive review of the published literature. 
Pharmacoeconomics, 21, 1315-1330.  
Chade, D. C., Shariat, S. F., & Dalbagni, G. (2009). Intravesical therapy for urothelial carcinoma 
of the urinary bladder: a critical review. International Braz J Urol, 35, 640-650; discussion 
651.  
Fung, C., Pandya, C., Guancial, E., Noyes, K., Sahasrabudhe, D. M., Messing, E. M., & Mohile, 
S. G. (2014). Impact of bladder cancer on health related quality of life in 1,476 older 
Americans: a cross-sectional study. Journal of Urology, 192, 690-695. doi: 
10.1016/j.juro.2014.03.098 
Gilbert, S. M., Dunn, R. L., Hollenbeck, B. K., Montie, J. E., Lee, C. T., Wood, D. P., & Wei, J. 
T. (2010). Development and validation of the Bladder Cancer Index: a comprehensive, 
disease specific measure of health related quality of life in patients with localized bladder 
cancer. Journal of Urology, 183, 1764-1769. doi: 10.1016/j.juro.2010.01.013  
Gilbert, S. M., Wood, D. P., Dunn, R. L., Weizer, A. Z., Lee, C. T., Montie, J. E., & Wei, J. T. 
(2007). Measuring health-related quality of life outcomes in bladder cancer patients using 
the Bladder Cancer Index. Cancer, 109, 1756-1762.  
Gontero, P., Oderda, M., Mehnert, A., Gurioli, A., Marson, F., Lucca, I., . . . Chun, F. (2013). 
The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guerin instillation 
therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a 
prospective, randomized, phase II trial. Journal of Urology, 190, 857-862. doi: 
10.1016/j.juro.2013.03.097 
Griffiths, T. R. L. (2013). Current perspectives in bladder cancer management. International 
Journal of Clinical Practice, 67, 435-448. doi: 10.1111/ijcp.12075 
Karaoglu, I., van der Heijden, A. G., & Witjes, J. A. (2014). The role of urine markers, white 
light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of 
non-muscle invasive bladder cancer. World Journal of Urology, 32, 651-659. doi: 
10.1007/s00345-013-1035-1 
Koga, H., Ozono, S., Tsushima, T., Tomita, K., Horiguchi, Y., Usami, M., . . . Naito, S. (2010). 
Maintenance intravesical bacillus Calmette-Guerin instillation for Ta, T1 cancer and 
carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study 
	
	 33	
Group. International Journal of Urology, 17, 759-766. doi: 10.1111/j.1442-
2042.2010.02584.x 
Kowalkowski, M. A., Chandrashekar, A., Amiel, G. E., Lerner, S. P., Wittmann, D. A., Latini, 
D. M., & Goltz, H. H. (2014). Examining sexual dysfunction in non-muscle-invasive 
bladder cancer: results of cross-sectional mixed-methods research. Sexual Medicine, 2, 141-
151. doi: 10.1002/sm2.24 
Mohamed, N. E., Gilbert, F., Lee, C. T., Sfakianos, J., Knauer, C., Mehrazin, R., . . . Steineck, G. 
(2016). Pursuing Quality in the Application of Bladder Cancer Quality of Life Research. 
Bladder Cancer, 2(2), 139-149. doi:10.3233/BLC-160051 
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009). Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. 
Journal of Clinical Epidemiology, 62(10), 1006-1012. doi:10.1016/j.jclinepi.2009.06.005 
Mossanen, M., & Gore, J. L. (2014). The burden of bladder cancer care: direct and indirect costs. 
Current Opinion in Urology, 24, 487-491. doi: 10.1097/mou.0000000000000078 
National Coalition for Cancer Survivorship. (2004). Survivorship definitions. Retrieved from 
http://cancercontrol.cancer.gov/ocs/statistics/definitions.html  
National Cancer Institute. (2017). Bladder Cancer. Retrieved from 
https://www.cancer.gov/types/bladder 
Nord, H., Segersten, U., Sandgren, J., Wester, K., Busch, C., Menzel, U., . . . Diaz de Stahl, T. 
(2010). Focal amplifications are associated with high grade and recurrences in stage Ta 
bladder carcinoma. International Journal of Cancer, 126, 1390-1402. doi: 10.1002/ijc.24954 
Pluye, P., Robert, E., Cargo, M., Bartlett, G., O’Cathain, A., Griffiths, F., Boardman, F., Gagnon, 
M.P., & Rousseau, M.C. (2011). Proposal: a mixed methods appraisal tool for systematic 
mixed studies reviews. Retrieved from 
http://mixedmethodsappraisaltoolpublic.pbworks.com. 
Sanchez, A., & Wszolek, M. F. (2015). Bladder cancer: Quality of life in patients with non-
muscle-invasive bladder cancer. Nature Reviews Urology, 12, 186-188. doi: 
10.1038/nrurol.2015.12 
Schmidt, S., Frances, A., Lorente Garin, J. A., Juanpere, N., Lloreta Trull, J., Bonfill, X., . . . 
Ferrer, M. (2015). Quality of life in patients with non-muscle-invasive bladder cancer: one-
year results of a multicentre prospective cohort study. Urologic Oncology, 33, 19.e7-15. doi: 
10.1016/j.urolonc.2014.09.012 
Siegel, R. L., Miller, K. D., & Jemal, A. (2017). Cancer Statistics, 2017. CA: Cancer Journal for 
Clinicians, 67(1), 7-30. doi:10.3322/caac.21387 
	
	 34	
Sighinolfi, M. C., Micali, S., De Stefani, S., Mofferdin, A., Ferrari, N., Giacometti, M., & 
Bianchi, G. (2007). Bacille Calmette-Guérin intravesical instillation and erectile function: is 
there a concern? Andrologia, 39, 51-54. doi: 10.1111/j.1439-0272.2007.00762.x 
Singer, S., Ziegler, C., Schwalenberg, T., Hinz, A., Gotze, H., & Schulte, T. (2013). Quality of 
life in patients with muscle invasive and non-muscle invasive bladder cancer. Supportive 
Care in Cancer, 21, 1383-1393. doi: 10.1007/s00520-012-1680-8  
Surveillance, Epidemiology, and End Results Program. (2017). Cancer fact sheets: Bladder 
Cancer. Retrieved from http://seer.cancer.gov/statfacts/html/urinb.html 
Sylvester, R. J., van der Meijden, A. P. M., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, 
L., . . . Kurth, K. (2006). Predicting recurrence and progression in individual patients with 
stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients 
from seven EORTC trials. European Urology, 49(3), 466-477. 
doi:10.1016/j.eururo.2005.12.031 
Tiu, A., Jenkins, L. C., & Soloway, M. S. (2014). Active surveillance for low-risk bladder 
cancer. Urologic Oncology, 32, 33.e37-10. doi: 10.1016/j.urolonc.2012.12.003 
van der Aa, M. N., Bekker, M. D., van der Kwast, T. H., Essink-Bot, M. L., Steyerberg, E. W., 
Zwarthoff, E. C., . . . Elzevier, H. W. (2009). Sexual function of patients under surveillance 
for bladder cancer. BJU International, 104(1), 35-40. doi:10.1111/j.1464-
410X.2008.08333.x 
Wei, L., Li, Q., Liang, H., & Jianbo, L. (2014). The quality of life in patients during intravesical 
treatment and correlation with local symptoms. Journal of Chemotherapy, 26, 165-168. doi: 
10.1179/1973947813y.0000000126 
Wright, J. L., & Porter, M. P. (2007). Quality-of-life assessment in patients with bladder cancer. 
Nature Clinical Practice Urology, 4, 147-154. doi: 10.1038/ncpuro0750 
Yeung, C., Dinh, T., & Lee, J. (2014). The health economics of bladder cancer: an updated 
review of the published literature. Pharmacoeconomics, 32(11), 1093-1104. 
doi:10.1007/s40273-014-0194-2 
Yokomizo, A., Kanimoto, Y., Okamura, T., Ozono, S., Koga, H., Iwamura, M., . . . Naito, S. 
(2016). Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low 
Dose bacillus Calmette-Guerin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.  
Journal of Urology, 195(1), 41-46. doi:10.1016/j.juro.2015.08.075 
Yoshimura, K., Utsunomiya, N., Ichioka, K., Matsui, Y., Terai, A., & Arai, Y. (2005). Impact of 
superficial bladder cancer and transurethral resection on general health-related quality of 





CHAPTER 3: QUALITY OF LIFE AMONG NON-MUSCLE-INVASIVE BLADDER 
CANCER SURVIVORS: A POPULATION-BASED STUDY 
Introduction 
 The burden of bladder cancer is significant and growing with the aging population. In the 
1990s, approximately 50,000 United States (US) patients were diagnosed with bladder cancer 
annually. In 2017, this grew to 79,030 cases of bladder cancer diagnoses in the US (National 
Cancer Institute, 2018). In North Carolina, bladder cancer was the sixth most common cancer, 
with more than 2,500 people diagnosed with the disease in that state in 2017 (North Carolina 
State Center for Health Statistics, 2017). Bladder cancer is three times more common in men 
than women, and has the highest median age (73 years old) of all cancers at diagnosis (National 
Cancer Institute, 2018). Moreover, most (75%) incident cases are diagnosed as non-muscle-
invasive bladder cancer (NMIBC) (Babjuk et al., 2017).  
The therapeutic management of NMIBC includes the transurethral resection of bladder 
tumor (TURBT) with or without intravesical chemotherapy or immunotherapy. Depending on 
the chosen strategy, these treatments can be associated with several complications in the short- 
and long-term, such as pain, urinary problems, gastro-intestinal problems, infection, or 
inflammation (Rutherford, Costa, King, Smith, & Patel, 2017). Even with the recommended 
treatments, up to 33% of NMIBC survivors have a recurrence of NMIBC within the first year, 
increasing to approximately 50% by five years (Cambier et al., 2016). The risk of progression to 
muscle-invasive bladder cancer (MIBC) is much more heterogeneous. It occurs very rarely in the 
lower risk majority, but high risk subgroups of NMIBC survivors face risks of up to 45% within 
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five years (Sylvester et al., 2006). Due to the high rate of recurrence or progression, NMIBC 
survivors are required to have repeated invasive surveillance cystoscopies (as frequent as every 
three months) and intravesical treatments (Babjuk et al., 2017). Thus, NMIBC survivors live 
with an exceptional burden of surveillance and possible treatment for the rest of their lives after 
diagnosis, which in turn might affect their quality of life (QOL) due to symptoms such as anxiety 
and posttraumatic stress. 
Despite the disproportionate share of incident and prevalent bladder cancer patients living 
with NMIBC, much of the existing QOL literature in bladder cancer addresses the burdens of 
patients with MIBC, not NMIBC, and focuses primarily on the experience of patients receiving 
cystectomy with different urinary diversion methods as opposed to chemoradiation (Mohamed et 
al., 2016). Relatively fewer studies have assessed the impact of both the disease and the 
treatment on QOL in NMIBC patients to date (Chapter 2). Moreover, although a few studies 
have been conducted with a population-based sample of bladder cancer survivors, there is 
currently no population-based QOL study that is focused solely on NMIBC survivors (Chapter 
2). 
 The aim of the current study is therefore to address several gaps in our understanding of 
the disease and treatment effects on the QOL in NMIBC survivors. Specifically, the aim is to a) 
describe QOL in a population-based sample of NMIBC survivors; and b) examine the impact of 
sex, cancer stage, time since diagnosis, and treatment on QOL. This work may inform the design 
of supportive care interventions to enhance QOL for NMIBC survivors after treatment and 






This study was a cross-sectional descriptive survey of NMIBC survivors. The protocol 
was approved by the Institutional Review Board at the University of North Carolina at Chapel 
Hill. 
Participants  
 Potential participants were identified through the North Carolina Central Cancer Registry 
(CCR), which is the cancer data center for the population of North Carolina. Eligible individuals: 
a) had a confirmed diagnosis of NMIBC (stage Ta, T1, or carcinoma in situ); b) were 18 years or 
older; c) were one to six years post-diagnosis; and d) had completed initial cancer treatment. 
Data Collection Procedures 
 A total of 5,979 NMIBC patients were listed in the North Carolina CCR who had been 
diagnosed between 2010 and 2014 and who met the inclusion criteria. Of these, 2,000 potential 
participants were randomly selected and stratified by sex (1,500 males and 500 females to reflect 
the sex ratio of the target population). The potential participants were contacted by mail, 
according to Dillman’s method for mailed surveys (Dillman, Smyth, & Christian, 2014). The 
initial contact was through a mailed survey packet, which contained a letter of introduction, CCR 
brochure, consent form, future contact form, and self-administered questionnaire with a postage-
paid return envelope. One week after the survey packet was sent, reminder postcards were sent to 
the potential participants in order to encourage participation. The data were double-entered by 
the first author and one trained research assistant, and all the discrepancies were corrected by 





  Data were collected from the North Carolina CCR and through self-administered 
questionnaires. The instruments are described in detail below.  
Demographics and clinical characteristics. Demographics and clinical characteristics 
were obtained from the North Carolina CCR information and participants’ self-reports. The 12-
item self-administered comorbidity questionnaire (SCQ) (Sangha, Stucki, Liang, Fossel, & Katz, 
2003) was used to assess other health-related problems. The SCQ is comprised of 12 defined 
medical problems, namely heart disease, high blood pressure, lung disease, diabetes, ulcer or 
stomach disease, kidney disease, liver disease, anemia or other blood diseases, cancer, 
depression, osteoarthritis or degenerative arthritis, back pain, and rheumatoid arthritis.  
Quality of life. QOL was assessed by means of the Core questionnaire of the European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC 
QLQ-C30) version 3.0 (Aaronson et al., 1993) and a NMIBC disease-specific questionnaire 
(EORTC QLQ-NMIBC24) (Blazeby et al., 2014). The EORTC QLQ-C30 has 30 items and is 
comprised of a global health status scale, five functional scales (physical, role, emotional, 
cognitive, and social) and nine symptom scales/items (fatigue, nausea and vomiting, pain, 
dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The measure 
was developed specifically for assessing the health-related QOL of cancer patients and has been 
used previously in the bladder cancer population (Gontero et al., 2013; Singer et al., 2013; Wei, 
Li, Liang, & Jianbo, 2014). Each item in the global health status scale has a numerical rating 
scale from 1 to 7, and each item in the function and symptom scales has a four-point Likert scale 
from 1 (‘not at all’) to 4 (‘very much’). The EORTC QLQ-NMIBC24 is a 24-item questionnaire 
specifically for patients with NMIBC. The measure is a disease-specific QOL module assessing 
11 domains: urinary symptoms, intravesical treatment issues, future worries, bowel symptoms 
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and sexual functioning. Each item has a four-point Likert scale from 1 (‘not at all’) to 4 (‘very 
much’). Scores for the domains of the EORTC QLQ-C30 and EORTC QLQ-NMIBC24 can 
range from 0 to 100. A higher score indicates a higher (better) level of global health status or 
functioning, or a higher (worse) level of symptoms. In this study, the Cronbach’s alpha of the 
EORTC QLQ-C30 and EORTC QLQ-NMIBC24 were .94 and .87, respectively. 
Data Analysis  
  Chi-squared tests and t-tests were used to determine whether there was a significant 
difference between the participants (those who had filled out and returned their surveys) and the 
non-participants (those who had not returned their surveys). Descriptive statistics (means, 
median, standard deviation, range) were computed to examine the demographics, clinical 
characteristics and QOL in NMIBC survivors. T-tests and analysis of variance (ANOVA) were 
used to examine whether the QOL varied by sex, cancer stage, time since diagnosis, and 
treatment. All the statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., 
Cary, NC, USA).   
Results 
Sample Characteristics 
Of the 2,000 prospective participants who were mailed the surveys, 173 (8.7%) packages 
were returned undeliverable and 35 (1.8%) patients did not meet the inclusion criteria (no 
NMIBC by patient report, n = 6; unable to read and write a questionnaire by family report, n = 
10; or deceased, n = 19) (Figure 3.1). Of the remaining 1,792 survivors, 398 (22.2%) participants 
completed and returned their surveys. The participants were more likely to be white than non-
participants (94.5% vs. 88.1%, p < .001). Other demographic and clinical characteristic 
information from the registry did not differ between participants and non-participants (Table 
3.1). Twenty-two participants who did not answer all of the main outcome instruments were 
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excluded, leaving 376 participants whose responses were included in the analyses. The 22 
participants whose data were excluded were more likely to be older than those whose data were 
included in the analyses (81.5 ± 6.7 vs. 72.2 ± 9.2, p < .001), but other demographic and clinical 
characteristic information from the registry did not differ.  
Tables 3.2-3 indicate the sample characteristics of the participants. The majority were 
male (72.3%, n = 272), white (94.4%, n = 355), non-Hispanic (98.1%, n = 369), married or 
living with partner (75.5%, n = 284), and had some college/technical school education or higher 
(73.2%, n = 275). Mean age at enrollment was 72.2 years (SD = 9.2), and 83.2% (n = 313) were 
aged 65 years or older. The mean years since diagnosis was 3.4 years (SD = 1.5). Most of the 
participants had papillary transitional cell carcinoma (83.0%) and were diagnosed at stage Ta 
(66.5%). The majority of the participants (73.4%, n = 276) reported having received TURBT as 
the primary treatment, whereas only 5.6% (n = 21) had received a cystectomy. Of the 
participants, 36.2% and 43.4% had received intravesical chemotherapy and immunotherapy, 
respectively. Recurrence of NMIBC was reported by 40.7% (n = 153) of the participants. Most 
of them (71.3%, n = 268) reported having a history of smoking, and 10.6% were current smokers 
(n = 40; 28 males, 12 females). Fifty-four (14.4%) respondents also reported a history of other 
cancers (of which, prostate and skin cancers were the most prevalent). 
Quality of Life 
Table 3.4 shows the means and standard deviations for the QOL measures. The average 
global health status score was 73.6 and the average functioning scores ranged from 83.9 to 86.5, 
where higher scores indicated better QOL (possible range 0-100). The average scores of the top 
five symptom scales/items in EORTC QLQ-C30 (insomnia, fatigue, dyspnea, pain, and financial 
difficulties) ranged from 14.1 to 24.3, where higher scores indicated lower QOL (possible range 
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0-100). The average scores for NMIBC disease-specific QOL ranged from 5.0 to 48.5. The 
domains with the highest scores, which indicated lower QOL, were male sexual problems, 
female sexual problems, urinary symptoms, future worries, and bloating and flatulence. The 
average sexual function and sexual enjoyment scores for NMIBC specific QOL were 31.5 (SD = 
27.2) and 48.1 (SD = 39.0) respectively, where higher scores represented better QOL.  
Quality of life by sex. Constipation, diarrhea, sexual function, sexual intimacy, risk of 
contaminating partner, and sexual enjoyment varied significantly by sex (Table 3.5). Females 
had significantly higher levels of constipation and diarrhea (both p = .02). Males had 
significantly better sexual function (p < .0001) and sexual enjoyment (p < .0001) than females. 
However, males reported significantly more discomfort with sexual intimacy (p = .01) and 
higher levels of concern about contaminating their partners (p = .03). 
Quality of life by cancer stage at diagnosis. Global health status, physical functioning 
role functioning, social functioning, fatigue, dyspnea, financial difficulties, and intravesical 
treatment issues varied significantly by cancer stage at diagnosis (all p < .05; see Table 3.5). The 
highest level of global health status was shown in stage Ta, the next highest was in stage T1, and 
the lowest level was in stage Tis. Step-down tests indicated that the only significant pairwise 
difference in global health status was between stages Ta and Tis (p = .02). Stage Ta had the best 
physical, role, and social functioning, and had the least fatigue, dyspnea, and financial 
difficulties. Stage Tis had the worst physical functioning and dyspnea; Stage T1 had the worst 
role functioning, social functioning, fatigue, and financial difficulties. However, step-down tests 
indicated that only stages Ta and T1 differed significantly in physical functioning (p = .01), role 
functioning (p = .01), social functioning (p < .01), fatigue (p = .01), dyspnea (p = .04), and 
financial difficulties (p < .001). The highest level of intravesical treatment issues was reported in 
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stage Tis, the next highest was in stage T1, and the lowest was in stage Ta. Step-down tests 
showed that stages Ta and T1 both had significantly lower intravesical treatment issues than 
stage Tis (both p < .05).   
Quality of life by time since diagnosis. Pearson’s correlation was used to evaluate the 
relationship between each domain of QOL and time since diagnosis (Table 3.5). The only 
significant relationship was with sexual function, which improved over time since diagnosis (p 
= .04). To allow for possible non-linear relationships, time since diagnosis was re-coded as a 
three-level categorical variable and ANOVA was used to relate time since diagnosis to QOL. 
There were no significant relationships between this categorical variable and QOL. 
Quality of life by treatment. Urinary symptoms, sexual intimacy, risk of contaminating 
partner, and male sexual problems varied significantly by treatment (Table 3.5). The lowest level 
of urinary symptoms was reported in survivors who had had a cystectomy; the highest level was 
in TURBT + chemotherapy. The cystectomy group had the highest level of discomfort with 
sexual intimacy and the most male sexual problems, whereas the TURBT + immunotherapy 
group had the lowest discomfort with sexual intimacy and the least male sexual problems. The 
highest level of concerns about contaminating partner was found in the TURBT + chemotherapy 
+ immunotherapy group, and the lowest was in TURBT only.  
After observing the large QOL differences between cystectomy and non-cystectomy 
treatments, we conducted post-hoc analyses with the goal of understanding how cystectomy was 
associated with QOL and how QOL varied within the non-cystectomy treatments. Two sets of 
post-hoc analyses were conducted: 1) comparing QOL in cystectomy vs. other using t-tests and 
2) comparing QOL among the non-cystectomy groups using ANOVA, with step-down tests 
where necessary. When comparing cystectomy vs. non-cystectomy, it was found that non-
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cystectomy had significantly higher levels of urinary symptoms (p < .0001), better sexual 
function (p < .01), better sexual intimacy (p < .01), higher sexual enjoyment (p = .01), and lower 
levels of male sexual problems (p = .03) than cystectomy. In comparing the non-cystectomy 
groups, the risk of contaminating partner varied significantly by treatment. Step-down tests 
showed that the TURBT with intravesical chemotherapy, TURBT with intravesical 
immunotherapy, and TURBT with intravesical chemotherapy and immunotherapy had 
significantly higher concerns about the risk of contaminating partners than TURBT only (p = .03, 
p < .01, and p = .03, respectively).   
Discussion 
A population-based cohort was used for this study and the NMIBC cohort had relatively 
longer follow-up time (time since diagnosis) compared to cohorts in other NMIBC QOL studies. 
To the best of our knowledge, this is the first population-based study to examine the effect of 
NMIBC diagnosis and treatment on survivors’ health-related QOL. The bladder cancer cohort of 
this study had similar demographics (race, age, and gender) to the bladder cancer population in 
the US.  
The average global health status and functions scores of EORTC QLQ-C30 in this study 
were consistent with those of other studies of NMIBC patients using the same QOL instrument 
(Gontero et al., 2013; Koga et al., 2010; Wei et al., 2014) (Table 3.6). However, considering that 
the mean time since diagnosis in our study (3.4 ± 1.5 years, range 1-6 years) was longer than 
those of other studies (right after the induction instillation cycle – up to two years post-
diagnosis), the current study demonstrates that global health status and functions years after 
diagnosis and treatment were similar to those of the other studies that were measured soon after 
diagnosis. The average symptom scores of EORTC QLQ-C30 were similar to other studies 
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(Gontero et al., 2013; Koga et al., 2010; Wei et al., 2014) except for fatigue, insomnia, and 
financial difficulties. In our study, the NMIBC survivors, whose mean time since diagnosis was 
3.4 ± 1.5 years, had worse symptoms of fatigue and insomnia and higher financial difficulties 
than the survivors in other NMIBC studies, in which they were measured after the intravesical 
treatment or one year after the end of the maintenance cycle (two years post-diagnosis) (Gontero 
et al., 2013; Koga et al., 2010; Wei et al., 2014).  
The higher financial difficulties in our study (longer mean time since diagnosis) than 
those in the other studies suggest that NMIBC survivors continuously face financial problems 
due to bladder cancer care and surveillance. Multiple studies defined bladder cancer as having 
the highest cost to the health system per patient, from diagnosis to death among all cancer types 
(Botteman, Pashos, Redaelli, Laskin, & Hauser, 2003; Yeung, Dinh, & Lee, 2014). However, 
little work has been done to understand how financial burden affects the NMIBC survivors and 
their access to medical care. Further research about the financial burden in NMIBC populations 
is needed in the future to support them and ultimately reduce their financial burden.  
The average global health status score of our study (73.6 ± 21.7) was higher (better QOL) 
than the EORTC reference value (62.6 ± 22.2) of genitourinary cancer patients (Scott et al., 
2008) and the value (43.5 ± 22.8) of bladder cancer (both NMIBC and MIBC) patients in the 
Singer et al. (2013) study (Table 3.6). Also, the average function and symptoms scores of 
EORTC QLQ-C30 in our study indicate better QOL than those of the EORTC reference and the 
bladder cancer patients in the Singer et al. (2013) study. However, the genitourinary cancer 
population of the EORTC reference values was mainly kidney cancer (76%), followed by other 
genitourinary cancer (18%) and bladder cancer (5%). Also, the Singer et al. (2013) study had 
mostly MIBC patients (64%), and only 26% of the study participants were NMIBC patients 
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(another 10% were unknown). Because 82% of the participants had had cystectomies in the 
Singer et al (2013) study, we suspect that the study had lower global health status, lower 
functions, and worse symptoms than those of our study.  
Although NMIBC-specific symptoms and sexual function in this study (1-6 years since 
diagnosis) seemed to be better than those right after induction intravesical therapy and one year 
after the end of the maintenance intravesical therapy in the other NMIBC study (Gontero et al., 
2013), which used the same instrument (EORTC QLQ-NMIBC 24) to assess QOL, we found 
that one- to six-year NMIBC survivors still reported urinary symptoms, future worries, sexual 
intimacy problems, and male/female sexual problems (erectile difficulty, ejaculation problem, or 
vaginal dryness) (Table 3.7). Our findings about sexual problems are supported by a previous 
mixed-methods study (Kowalkowski et al., 2014). The previous study also demonstrated that 
NMIBC participants (mean age was 65 years), who had been diagnosed within four years, 
reported sexual dysfunction such as erection difficulty (60% of sexually active males), 
ejaculation problem (43.1% of sexually active males), and vaginal dryness (62.5% of sexually 
active females). This prevalence of sexual dysfunction in NMIBC survivors was much higher 
than community-dwelling older adults (57 to 85 years) in the US: erection difficulty (37% of 
sexually active males) and vaginal dryness (39% of sexually active females) (Lindau et al., 
2007).   
In our study, global health status and most functions and symptoms did not vary by sex, 
but bowel problems and sexual issues did. Females had more severe bowel problems, lower 
sexual function, and lower sexual enjoyment than males, but better sexual intimacy and fewer 
concerns about contaminating their partners. Schmidt et al. (2015) assessed QOL in NMIBC 
patients within a year of diagnosis, and found no difference in QOL (physical, mental, urinary, 
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bowel, and sexual QOL) by sex. The findings could be different from ours due to the use of 
different QOL instruments and time since diagnosis (our study population was at least one-year 
post-diagnosis). However, the differences in sexual issues by sex are also shown in some other 
studies (Kowalkowski et al., 2014; van der Aa et al., 2009), which reported that males were 
significantly more sexually active than females. 
Interestingly, QOL did not vary by time since diagnosis except for sexual function in this 
study, which is consistent with other studies (Allareddy, Kennedy, West, & Konety, 2006; Fung 
et al., 2014; Kowalkowski et al., 2014). These findings suggest that NMIBC survivors had 
lifelong burdens that were different from those associated with other cancers. For many other 
cancers, including MIBC, there is a relatively intense period of treatment (major surgery and 
potentially chemotherapy/radiation) shortly after diagnosis; then patients shift into survivorship 
mode, which is often relatively static, with noninvasive (scan-based) surveillance, and relatively 
less frequent recurrence. However, the NMIBC population has much higher rates of recurrence 
(> 40%) than most cancers, and this might be a burden that affects their QOL for the rest of their 
lives. Allareddy et al. (2006) assessed QOL in long-term bladder cancer survivors (both NMIBC 
and MIBC) and showed that QOL scores did not differ by time since diagnosis. One cross-
sectional study reported significant differences of mental and physical QOL between the pre- and 
post-diagnoses (five years for mental QOL; 10 years for physical QOL) groups (Fung et al., 
2014). These findings suggest that QOL decreases after a cancer diagnosis and does not improve 
for many years. However, this needs to be interpreted with caution, because those studies were 
cross-sectional in design. Thus, a longitudinal study may provide a better understanding of QOL 
by time since diagnosis. In this study, sexual function, which indicates the extent of sexual 
activity and interest in sex, was better in survivors who were farther from the time of diagnosis. 
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Kowalkowski et al. (2014) also found that time since diagnosis was significantly longer in 
participants who had an interest in sex than those who had no interest in sex.  
Global health status was significantly higher in stage Ta than in stage Tis. In addition, 
stage Ta had significantly better QOL than stage T1 in terms of physical functioning, role 
functioning, social functioning, fatigue, dyspnea, and financial difficulties. Stage Ta had the 
lowest intravesical treatment issues, and stages Ta and T1 had significantly lower intravesical 
treatment issues than stage Tis. One possible explanation for these findings is that at stage Ta 
there is often a lower risk of progression, so patients diagnosed at stage Ta less commonly 
receive intravesical immunotherapy or other treatments. However, considering intravesical 
immunotherapy is generally used more in Tis, as well as T1, the finding that only Tis appears to 
be substantially different to the other two (T1 and Ta) for intravesical treatment issues may be 
explained in part by the small number of participants at stage Tis (n=24, 6.4%). 
The cystectomy group had better QOL in terms of urinary symptoms and worse QOL in 
terms of sexual function, discomfort with sexual intimacy, sexual enjoyment, and male sexual 
problems than the non-cystectomy group, which is in agreement with previous studies 
(Allareddy et al., 2006; Gilbert et al., 2007). The results from our study suggest that TURBT 
only group had significantly less concerns about the risk of contaminating their partners than the 
other treatment groups (TURBT + chemotherapy, TURTB + immunotherapy, TURBT + 
chemotherapy + immunotherapy). However, there were no significant differences in general 
health status, functions (physical, role, emotional, cognitive, and social functions), and common 
cancer symptoms between the cystectomy and the non-cystectomy groups. The number of 
survivors in the cystectomy group was too small (n = 21) for further comparison. 
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This study has several limitations. Firstly, because we used a cross-sectional design, we 
are not able to infer longitudinal changes in QOL. Also, we did not have pre-treatment baseline 
QOL data for comparison; thus, potential differences in the baseline characteristics of 
participants exist. A longitudinal study, which is currently lacking in the literature on QOL in the 
NMIBC population, would provide better information about QOL changes over time. Another 
limitation of this study is the lower response rate (22%) when compared to the similar survey 
studies used samples from other state cancer registry populations (cancer survivors from the 
Cancer Prevention Institute of California’s cancer registry 49.2%; adolescent and young adult 
cancer survivors from 7 Surveillance, Epidemiology, and End-Results cancer registries 43%) 
(Arora, Reeve, Hays, Clauser, & Oakley-Girvan, 2011; Harlan et al., 2011). This might have 
been due to our inability to do multiple follow-up mailings due to cost. Lastly, while the large 
majority of the patients in the cohort was white (89.5%), reflective of the demographics of 
bladder cancer in the US in general, the participants were more likely white (94.5%) than non-
participants (88.1%). Almost nothing is known about QOL in minority populations with 
NMIBC. Thus, more studies should be conducted in a more diverse NMIBC population to 
confirm the generalizability of our findings to diverse populations.  
One strength of this study is the use of a population-based sample to assess the burdens of 
the unique and understudied NMIBC population. To the best of our knowledge, there have been 
no NMIBC QOL studies in which population-based sampling was used. Our study sample was 
randomly selected from the NMIBC population in North Carolina, which is similar to the 
demographics of those in the US; thus the findings of this study can be generalized to all US 
NMIBC survivors. Another strength of this study is the use of a validated QOL instrument, 
namely EORTC QLQ-C30, which assesses common QOL aspects in cancer. Furthermore, 
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EORTC QLQ-NMIBC24 was used to measure NMIBC-specific QOL, such as urinary, bowel, 
and sexual problems. The findings from this study provide reliable and valid knowledge about 
specific QOL issues among NMIBC survivors due to the use of both general and disease-specific 
cancer QOL instruments in a population-based sample. 
Conclusion 
This population-based study provides information about the impact of disease and 
treatment on QOL among NMIBC survivors. Most of the existing QOL studies in bladder cancer 
are focused on MIBC, especially patients with MIBC who had cystectomies, which was a big life 
change. However, NMIBC survivors represent the majority of incident and prevalent cases of 
bladder cancer. In addition, although NMIBC has relatively lower oncological risk than MIBC, 
NMIBC survivors face a unique burden associated with their diagnosis and an often-lifelong 
surveillance and treatment regimen. Urinary and bowel symptoms, sexual problems, and future 
worries persisted in one to six-year NMIBC survivors. Moreover, global health status, functions 
(physical, role, social), and financial difficulties differed by cancer stage; and sexual QOL 
differed by sex and type of treatment. These findings suggest that healthcare providers should 
regularly assess these burdens across the continuum of care for NMIBC survivors and provide 
appropriate resources by sex, stage, and treatment. However, little is known about supportive 
care interventions targeting the unique needs of this population. More studies are needed to 
better understand these unique needs and to develop appropriate supportive care interventions for 
NMIBC survivors.  
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Note. *All patients diagnosed with NMIBC in 2010-2014 and registered in NC central cancer registry 
were eligible for this study. 
 †Chi-squared tests and t-tests were used for categorical and continuous variables, respectively. 
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Table 3.2. Demographics from NC Central Cancer Registry and Survey  
Characteristic Participants (n=376*) 
Sex† 
  Male 




Age at diagnosis, years† 
Mean (SD), Range 
 
68.3 (9.2), 34-89 
Age at enrollment, years† 
Mean (SD), Range 
 






























≤ High school graduate 
Some college or technical school/College graduate 
Post-graduate 






Marital status  
Married/ Living with partner 
Never married/ Divorced/ Widowed/ Separated 







Unemployed, [Unemployed & < 65 years] 
Retired 
No response given 
 
71 (18.9%) 
20 (5.3%), [9] 
274 (72.9%) 
11 (2.9%) 
Current health care coverage 
Don’t have 
Private insurance 
Government health care coverage (Medicare, Medicaid) 






Note. * 22 respondents, who did not answer at least one of the main outcome (uncertainty, PTSD, quality 
of life) instruments, were excluded in the analysis. 







Table 3.3. Clinical Characteristics from NC Central Cancer Registry and Survey 
Characteristic Participants (n=376*) 
Histology† 
Papillary transitional cell carcinoma 














Years since diagnosis† 
Mean (SD), Range 
 
3.4 (1.5), 1-6 




Removal of bladder 
Radiation therapy 
Other 





















Current treatment status 
Not in treatment 
Receiving treatment 








































2.7 (5.0), 1-60 
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Characteristic Participants (n=376*) 







No response given  
 










7.9 (7.6), 0-100 







No response given  
 










1.9 (1.4), 0-12 
Current cystoscopy frequency 
   Per 0-3 months 
Per 4-6 months 
Per 7-11 months 
Per 1 year 
Per 2 years 
Only had once 












No response given 
 
40 (10.6%)   
329 (87.5%) 
7 (1.9%) 
Number of comorbidity  

















New other cancers 
Yes  
No 





Note. * 22 respondents, who did not answer at least one of the main outcome (uncertainty, PTSD, quality 
of life) instruments, were excluded in the analysis.  
† Data from NC central cancer registry. 
	
	 54	
Table 3.4. Mean Scores, Possible and Actual Score Ranges for Quality of Life 




Global health status 364 73.6 (21.7) 0 - 100 
Physical functioning 376 84.6 (20.3) 6.7-100 
Role functioning 376 86.5 (23.9) 0 - 100 
Emotional functioning 376 84.4 (21.0) 0 - 100 
Cognitive functioning 376 83.9 (21.3) 0 - 100 
Social functioning 376 84.8 (25.1) 0 - 100 
Fatigue† 376 23.6 (25.6) 0 - 100 
Nausea and vomiting† 376 5.1 (12.0) 0 – 66.7 
Pain† 376 16.4 (25.3) 0 - 100 
Dyspnea† 376 17.1 (27.2) 0 - 100 
Insomnia† 374 24.3 (30.4) 0 - 100 
Appetite loss† 374 9.0 (20.5) 0 - 100 
Constipation† 374 13.7 (24.9) 0 - 100 
Diarrhea† 375 9.2 (18.8) 0 - 100 
Financial difficulties† 376 14.1 (26.2) 0 - 100 
EORTC QLQ-
NMIBC24 
Urinary symptoms† 375 23.5(22.2) 0 - 100 
Malaise† 376 5.0 (11.8) 0 – 83.3 
Future worries† 376 23. 5 (22.7) 0 - 100 
Bloating & flatulence† 376 20.5 (21.5) 0 - 100 
Sexual function 368 31. 5 (27.2) 0 - 100 
Intravesical treatment issues† 375 7.4 (18.8) 0 - 100 
Sexual intimacy† 352 27.9 (35.0) 0 -100 
Risk of contaminating partner† 350 9.7 (23.7) 0 - 100 
Sexual enjoyment 327 48.1 (38.1) 0 - 100 
Male sexual problems† 261 48.5 (35.7) 0 - 100 
Female sexual problems† 83 39.0 (39.2) 0 - 100 
Note. Possible range is 0-100.  






Table 3.5. Quality of Life by Sex, Stage, and Years since Diagnosis 



























































































































83.7 (22.8)  
.48 














































74.8 (19.1)  











































Note. + Higher score indicates better QOL; - Higher score indicates worse QOL 
 a. p-value from t-test; b. p-value from one-way ANOVA; c. p-value from Pearson’s correlation; d. p-
value for post-hoc t-test of cystectomy vs. non-cystectomy; e. p-value for post-hoc ANOVA within the 4 
non-cystectomy treatments (i.e., excluding cystectomy) 
 § Treatment data were not complete; n=345 for global health status; n=357 for function, symptom, 
malaise, future worries, and bloating & flatulence; n=356 for urinary symptom, intravesical treatment 
issues; n=349 for sexual function; n=333 for sexual intimacy; n=331 for risk of contaminating partner; 



























































































































24.2 (32.9)  
.41 














































87.3 (24.8)  











































Note: + Higher score indicates better QOL; - Higher score indicates worse QOL 
 a. p-value from t-test; b. p-value from one-way ANOVA; c. p-value from Pearson’s correlation; d. p-
value for post-hoc t-test of cystectomy vs. non-cystectomy; e. p-value for post-hoc ANOVA within the 4 
non-cystectomy treatments (i.e., excluding cystectomy) 
 § Treatment data were not complete; n=345 for global health status; n=357 for function, symptom, 
malaise, future worries, and bloating & flatulence; n=356 for urinary symptom, intravesical treatment 
issues; n=349 for sexual function; n=333 for sexual intimacy; n=331 for risk of contaminating partner; 

























































































































































































































Note: + Higher score indicates better QOL; - Higher score indicates worse QOL 
 a. p-value from t-test; b. p-value from one-way ANOVA; c. p-value from Pearson’s correlation; d. p-
value for post-hoc t-test of cystectomy vs. non-cystectomy; e. p-value for post-hoc ANOVA within the 4 
non-cystectomy treatments (i.e., excluding cystectomy) 
 § Treatment data were not complete; n=345 for global health status; n=357 for function, symptom, 
malaise, future worries, and bloating & flatulence; n=356 for urinary symptom, intravesical treatment 
issues; n=349 for sexual function; n=333 for sexual intimacy; n=331 for risk of contaminating partner; 




























































































































































































































Note. + Higher score indicates better QOL; - Higher score indicates worse QOL 
 a. p-value from t-test; b. p-value from one-way ANOVA; c. p-value from Pearson’s correlation; d. p-
value for post-hoc t-test of cystectomy vs. non-cystectomy; e. p-value for post-hoc ANOVA within the 4 
non-cystectomy treatments (i.e., excluding cystectomy) 
 § Treatment data were not complete; n=345 for global health status; n=357 for function, symptom, 
malaise, future worries, and bloating & flatulence; n=356 for urinary symptom, intravesical treatment 
issues; n=349 for sexual function; n=333 for sexual intimacy; n=331 for risk of contaminating partner; 

























































































































































































Note. + Higher score indicates better QOL; - Higher score indicates worse QOL 
 a. p-value from t-test; b. p-value from one-way ANOVA; c. p-value from Pearson’s correlation; d. p-
value for post-hoc t-test of cystectomy vs. non-cystectomy; e. p-value for post-hoc ANOVA within the 4 
non-cystectomy treatments (i.e., excluding cystectomy) 
 § Treatment data were not complete; n=345 for global health status; n=357 for function, symptom, 
malaise, future worries, and bloating & flatulence; n=356 for urinary symptom, intravesical treatment 
issues; n=349 for sexual function; n=333 for sexual intimacy; n=331 for risk of contaminating partner; 





 EORTC QLQ-NMIBC24 
Mean (SD) 
 Male sexual problems 
(n=261) 
- 

























































































Note. + Higher score indicates better QOL; - Higher score indicates worse QOL. 
 a. p-value from t-test; b. p-value from one-way ANOVA; c. p-value from Pearson’s correlation; d. p-
value for post-hoc t-test of cystectomy vs. non-cystectomy; e. p-value for post-hoc ANOVA within the 4 
non-cystectomy treatments (i.e., excluding cystectomy). 
 § Treatment data were not complete; n=345 for global health status; n=357 for function, symptom, 
malaise, future worries, and bloating & flatulence; n=356 for urinary symptom, intravesical treatment 
issues; n=349 for sexual function; n=333 for sexual intimacy; n=331 for risk of contaminating partner; 






Table 3.6. Quality of Life (EORTC QLQ-C30) Comparison with the Other Studies  


















1y after the 




Global health status 73.6 (21.7) 62.6 (22.2) 43.5 (22.8) 83.3 (11.8) 74.5 (17.2) 66.0 (17.6) 76.5 (15.3) 78.5 (14.7) 
Physical functioning 84.6 (20.3) Previous version: 
NA 
55.6 (21.9) 94.3 (11.4) 93.3 (12.5) 89.5 (16.6) 88.7 (15.7) 86.1 (18.3) 
Role functioning 86.5 (23.9) 56.8 (33.5) 36.6 (33.8) 95.9 (10.2) 97.5 (7.6) 88.5 (14.0) 91.9 (17.8) 89.4 (22.1) 
Emotional functioning 84.4 (21.0) 74.7 (22.9) 51.3 (27.6) 98.7 (3.8) 97.8 (4.9) 88.1 (11.1) 84.2 (18.9) 84.3 (21.7) 
Cognitive functioning 83.9 (21.3) 86.6 (18.2) 70.4 (28.9) 85.4 (15.4) 83.3 (16.6) 80.1 (14.2) 90.0 (15.8) 86.6 (23.4) 
Social functioning 84.8 (25.1) 71.7 (28.2) 52.5 (32.2) 100 (0) 83.6 (15.4) 89.7 (15.0) 89.8 (20.0) 90.0 (17.1) 
Fatigue† 23.6 (25.6) 35.7 (28.6) 63.7 (27.6) 4.4 (10.7) 5.5 (12.9) 19.2 (14.9) 13.4 (19.3) 13.4 (18.8) 
Nausea and vomiting† 5.1 (12.0) 6.0 (13.5) 13.2 (23.3) 0 (0) 0 (0) 0 (0) 6.6 (15.4) 10.0 (19.7) 
Pain† 16.4 (25.3) 27.0 (29.7) 43.8 (34.5) 3.3 (9.6) 8.8 (12.0) 18.0 (25.4) 9.7 (17.2) 12.9 (20.2) 
Dyspnea† 17.1 (27.2) 16.5 (25) 38.8 (35.3) 6.3 (13.1) 5.0 (16.4) 9.0 (17.8) 11.2 (20.2) 13.6 (21.8) 
Insomnia† 24.3 (30.4) 26.3 (29.2) 48.1 (37.4) 1.9 (7.7) 1.3 (6.4) 16.8 (19.4) 15.0 (22.3) 16.3 (25.3) 
Appetite loss† 9.0 (20.5) 16.5 (27.6) 40.7 (39.4) 0.94 (5.6) 1.26 (6.4) 3.9 (10.9) 7.7 (20.4) 9.5 (19.5) 
Constipation† 13.7 (24.9) 18.9 (30) 29.0 (36.8) 0.9 (5.6) 0.62 (4.6) 18.0 (27.1) 11.8 (19.9) 13.6 (21.2) 
Diarrhea† 9.2 (18.8) 8.3 (19.8) 22.3 (32.7) 0 (0) 3.8 (14.0) 2.6 (9.1) 7.4 (17.1) 9.5 (18.2) 
Financial difficulties† 14.1 (26.2) 15.1 (26.1) 22.6 (31.1) 0.94 (5.6) 7.5 (14.0) 6.4 (13.4) 1.5 (6.9) 1.9 (7.8) 
   GU cancer 
n=246 (Bladder 
5%, Kidney 
76%, other 18%) 
Stage (I-II 9%, 
III-IV 65%, 
recurrent/meta 














M 82, F 24 
Age (<40 =12; 
40-60 =34; 
 >60 =60) 
Average 
age=61(15.5) 
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Table 3.7. Quality of Life (EORTC QLQ-NMIBC24) Comparison with the Other Studies   
Measure Characteristic Mean (SD) Gontero (2013) 











Urinary symptoms† 23.5(22.2) 84.1 (16.2) 81.7 (14.3) 
Malaise† 5.0 (11.8) NA NA 
Future worries† 23. 5 (22.7) 52.0 (14.2) 50.5 (15.8) 
Bloating & flatulence† 20.5 (21.5) 85.7 (20.9) 86.6 (15.5) 
Sexual function 31. 5 (27.2) 70.8 (7.1) 71.6 (5.2) 
Intravesical treatment issues† 7.4 (18.8) 81.3 (13.5) 78.4 (11.0) 
Sexual intimacy† 27.9 (35.0) NA NA 
Risk of contaminating partner† 9.7 (23.7) NA NA 
Sexual enjoyment 48.1 (38.1) NA NA 
Male sexual problems† 48.5 (35.7) NA NA 
Female sexual problems† 39.0 (39.2) NA NA 
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CHAPTER 4: RELATIONSHIPS AMONG UNCERTAINTY, POST-TRAUMATIC 
STRESS DISORDER SYMPTOMS, AND QUALITY OF LIFE IN NON-MUSCLE-
INVASIVE BLADDER CANCER SURVIVORS 
Introduction 
In the United States (US), more than 696,000 people were living with bladder cancer in 
2014 (National Cancer Institute, 2018). Approximately 75% of newly diagnosed bladder cancer 
cases are classified as non-muscle-invasive bladder cancer (NMIBC) (Sanchez & Wszolek, 
2015). NMIBC has the highest recurrence rate of any cancer site and, in some cases, there is a 
high risk of progression to the potentially lethal phenotype of muscle-invasive bladder cancer.  
Against this backdrop, NMIBC survivors are required to have frequent surveillance cystoscopies 
and, often, repeated intravesical treatments for the remainder of their lives (Babjuk et al., 2017).  
Given the high recurrence rate, repeated treatments, and surveillance cystoscopies, 
NMIBC survivors may struggle with cancer-related uncertainty about long-term treatments’ side 
effects, recurrence, and their future health. Uncertainty in illness is defined as the lack of ability 
to determine the meaning of illness-related events and is generated in a situation when a person 
is unable to predict outcomes accurately (Mishel, 1988). Cancer-related uncertainty can be 
related to fears of cancer recurrence or the appearance of a secondary cancer after curative 
treatment, the presence of symptoms and comorbidities, side effects of treatments, and financial 
concerns about health-related costs (Gill et al., 2004; Mast, 1998). In cancer patients and 
survivors, higher levels of uncertainty have been associated with greater levels of emotional 
distress and poorer quality of life (QOL) (Clayton, Mishel, & Belyea, 2006; Mast, 1998; 
Sammarco & Konecny, 2010). 
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Individuals who experience uncertainty can develop symptoms similar to those seen in 
people with post-traumatic stress disorder (PTSD) (Mishel, 1990). PTSD is a mental health 
problem that can develop after exposure to a traumatic event (American Psychiatric Association, 
2013). A substantial amount of research has been conducted on PTSD symptoms (PTSS) and 
PTSD in cancer populations. A meta-analysis revealed that the prevalence of cancer-related 
PTSD in adult cancer survivors ranged from 7.3% to 13.8% using self-report screening (Abbey, 
Thompson, Hickish, & Heathcote, 2015). Studies in which structured clinical interview methods 
were used revealed a mean prevalence of 6.4% for current cancer-related PTSD and 12.6% for 
lifetime cancer-related PTSD in cancer survivors (Abbey et al., 2015). In contrast, the general 
US adult population is estimated to have a current PTSD prevalence of 3.5% and a lifetime 
PTSD prevalence of 6.8% (Gradus, 2017). In addition, 10-20% of patients with cancer had 
subsyndromal levels of PTSS (e.g., partial PTSD) (Cordova, Riba, & Spiegel, 2017). Previous 
studies have shown that the observed higher levels of PTSS and PTSD are associated with poorer 
QOL in cancer populations (Amir & Ramati, 2002; Geffen, Blaustein, Amir, & Cohen, 2003; 
Gold et al., 2012; S. K. Smith, Williams, Zimmer, & Zimmerman, 2011).  
The burdens of NMIBC survivorship include many sources of uncertainty and risk factors 
for PTSS. However, cancer-related uncertainty and PTSS have not been studied in NMIBC 
survivors. Thus, in this study the prevalence of uncertainty and PTSS in NMIBC survivors was 
examined. In addition, a theoretical model was developed and tested using structural equation 
modeling (SEM) to assess the effects of multiple factors on QOL and to explore the relationship 
among uncertainty, PTSS, and QOL. The findings of this study may facilitate further 
understanding of the complexity of factors that influence NMIBC survivors’ QOL during their 




The conceptual framework for this study (Figure 4.1) was adapted from Smith, Williams, 
Zimmer, and Zimmerman’s model (S. K. Smith et al., 2011). The model is based on the Stress, 
Appraisal, and Coping Theory, in which the relationship between the person (his/her 
characteristics) and his/her environment (stressor: cancer treatment and surveillance experience) 
is emphasized (Folkman, Lazarus, Gruen, & DeLongis, 1986), as well as the Uncertainty in 
Illness Theory (Mishel, 1988). The model for this study has five components: demographic 
characteristics, psychosocial characteristics, stressors, psychological effects, and outcomes. 
Clinical characteristics (e.g., cancer diagnosis, treatment, surveillance cystoscopy) and general 
health and health-behavior status (e.g., other cancer, comorbidities, smoking) are conceptualized 
as stressors. Demographic characteristics and psychosocial characteristics (e.g., social support, 
cognition) can influence the outcome of these stressors. This framework suggests that the three 
sets of antecedent variables (demographics, psychosocial characteristics, and stressors) can 
directly or indirectly influence the experience of uncertainty and PTSS. This framework also 
suggests that the experience of uncertainty and PTSS can influence QOL. In addition, 
demographics, psychosocial characteristics, and stressors can directly or indirectly affect QOL 









This study is a cross-sectional descriptive survey. Data from a survey conducted among 
bladder cancer survivors (Chapter 3) was used for this study, which was reviewed and approved 
by the Institutional Review Board at the University of North Carolina at Chapel Hill. 
Participants and Data Collection Procedures 
 Eligible participants (N = 5,979) were identified through the North Carolina Central 
Cancer Registry (CCR). Eligibility criteria for the study included: a) a formal diagnosis of non-
muscle-invasive bladder cancer (stage Ta, T1 and carcinoma in situ); b) 18 years or older; c) 
between one and six years post-diagnosis; and d) completed initial NMIBC cancer treatment. Of 
the 5,979 eligible participants, 2,000 were randomly selected and contacted by mail. Adapted 
from the Dillman’s method for mailed surveys (Dillman, Smyth, & Christian, 2014), survivors 
were mailed a survey packet containing a letter of introduction, a CCR brochure, a consent form, 
a future contact form, and a self-administered questionnaire with a postage-paid return envelope. 
The survivors received a reminder postcard one week after the survey packet was mailed out.  
Measures 
  Data were collected from the North Carolina CCR and through the self-administered 
questionnaires. The instruments are described in detail below.  
Demographics and clinical characteristics. Demographics and clinical information 
were collected from the North Carolina CCR and the participants’ self-reports. Other health-
related problems were assessed by means of the 12-item Self-Administered Comorbidity 
Questionnaire (SCQ) (Sangha, Stucki, Liang, Fossel, & Katz, 2003). 
Psychosocial characteristics. The perceived availability of social support was measured 
by the 19-item Medical Outcomes Study (MOS) Social Support Survey (Sherbourne & Stewart, 
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1991). Each item has a five-point Likert scale that ranges from 1 (‘none of the time’) to 5 (‘all of 
the time’). The total score can range from 19 to 95, with higher scores reflecting higher support. 
In this study, the Cronbach’s alpha of the MOS was .98. 
Cognition was assessed using the PROMIS Applied Cognition – Abilities Short Form 
v.1.0 and the PROMIS Applied Cognition – General Concerns Short Form v.1.0 (Cella et al., 
2010), each of which has eight items on a five-point Likert scale. The total score for each 
construct can range from 8 to 40, with higher scores indicating higher (better) cognitive abilities 
or greater (worse) cognitive general concerns. In this study, the Cronbach’s alpha of the 
PROMIS Applied Cognition –Abilities and General Concerns were .98 and .97, respectively. 
Uncertainty. The Mishel Uncertainty in Illness Scale-Survivor (MUIS-S) (Mishel, 1997) 
was used to measure the perceptions of uncertainty of the cancer survivors. The MUIS-S has 22-
items to assess uncertainty in the areas of symptomatology, treatment, relationship with 
caregivers, and planning for the future. Each item has a five-point Likert scale that ranges from 
‘strongly agree’ to ‘strongly disagree’. Items 6, 8, 18, 19, 21, and 22 are reverse coded on the 
scale. The total score was calculated by totaling the response scores for each of the 22 items, 
with a total score range of 22 to 110. A higher score on the MUIS-S indicates a greater level of 
uncertainty. In this study, the Cronbach’s alpha of the MUIS-S was .87. 
Post-traumatic stress disorder symptoms. The PTSD Checklist for DSM-5 (PCL-5) 
(Weathers et al., 2013) was used to assess PTSS. The PCL-5 has 20 items, which correspond 
with the symptom criteria for PTSD in the Diagnostic and Statistical Manual of Mental 
Disorders, Fifth edition (DSM-5) (American Psychiatric Association, 2013). The PCL-5 
instructions were modified for participants to respond with regard to their diagnosis and 
treatment for bladder cancer. Each item has a five-point Likert scale from 0 (‘not at all’) to 4 
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(‘extremely’). The total symptom score, ranging from 0 to 80, was obtained by totaling the 
scores for each of the 20 items. A higher score represents a higher level of PTSS. Two 
approaches were used to identify a provisional PTSD diagnosis: 1) the total symptom score of 33 
(cut-point) or higher; 2) treating each item rated as 2 (‘moderately’) or higher as a symptom 
endorsed, then, following the DSM-5 diagnostic rule, which requires one or more intrusion 
symptoms (questions 1-5), one or more avoidance symptoms (questions 6-7), two or more 
negative cognitions and mood symptoms (questions 8-14), and two or more arousal symptoms 
(questions 15-20) (American Psychiatric Association, 2013; Weathers et al., 2013). In this study, 
the Cronbach’s alpha of the PCL-5 was .94.  
QOL. The Core questionnaire of the European Organization for Research and Treatment 
of Cancer (EORTC QLQ-C30) version 3.0 (Aaronson et al., 1993) was used to assess QOL. The 
EORTC QLQ-C30 has 30 items, and is comprised of three domains: global health status, 
function, and symptom. The function domain is measured by five function subscales (physical 
function, role function, emotional function, cognitive function, and social function). We 
computed a total function domain score from the items in all five function scales. The symptom 
domain consists of nine symptom subscales/items (fatigue, nausea and vomiting, pain, dyspnea, 
insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a total symptom 
domain score was computed from all symptom items. The measure was developed specifically 
for assessing the health-related QOL of cancer patients and has been used previously in the 
bladder cancer population (Gontero et al., 2013; Singer et al., 2013; Wei, Li, Liang, & Jianbo, 
2014). Each item in the global health status scale has a numerical rating scale from 1 to 7, and 
each item in the function and symptom scales has a four-point Likert scale from 1 (‘not at all’) to 
4 (‘very much’). For each of the three domains, the raw score was calculated by averaging the 
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response scores of items. Raw scores were linearly transformed to have a possible range from 0 
to 100.  Higher score indicates a higher (better) level of global health status or functioning, or a 
higher (worse) level of symptoms. In this study, the Cronbach’s alpha of the global health status, 
function, and symptom scales were .92, .94, and .91, respectively. 
Data Analysis  
  Descriptive statistics (means, median, standard deviation, range) were computed to 
examine the demographics, clinical characteristics, level of uncertainty, PTSS, and QOL of the 
NMIBC survivors. To explore the relationships among uncertainty, PTSS and QOL, Pearson and 
point biserial correlations were calculated.  
Hierarchical multiple linear regressions with backward selection were used to determine 
which covariates predicted uncertainty, PTSS, and QOL. The covariates were grouped into four 
categories (Table 4.1), with each category added sequentially to a multiple linear regression 
model. To maintain parsimony, after each category was added, backward selection was used to 
reduce the model, dropping the variable with the highest p-value until all the remaining variables 
had p < .20. This cutoff was chosen to yield a parsimonious model without being overly 
restrictive. Sex, race/ethnicity and age at study enrollment were always kept in the model 
regardless of p-value. Though predictors remained in the model when p < .20, statistical 
significance was set at p < .05. Descriptive statistical and multiple regression analyses were 
performed using SAS version 9.4.  
SEM was used to assess how the antecedents (personal characteristics) related to the 
mediators (uncertainty, PTSS) and the outcome (QOL), and how the potential mediators and the 
outcome were related. First, we employed a measurement model (confirmatory factor analysis 
(CFA)) to test whether the three observed variables of QOL could be coherently summarized in a 
single latent variable. In CFA, higher factor loadings and R2 values indicate a stronger 
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relationship between the observed variables and their indicator; if any of the factor loadings are 
weak (< .40) or any of the R2 are low (< .50), that QOL measure may not fit appropriately in the 
model (Baron & Kenny, 1986; Bollen, 1989; Kline, 2016). Second, path analysis was performed 
to examine the relationships among the personal characteristics (disease characteristics, 
health/health behavior status, and psychosocial factors), uncertainty, PTSS, and QOL of the 
NMIBC survivors. In particular, the hypothesized mediation model presented in Figure 4.2 was 
built and assessed using path analysis. Based on the results of multiple regression analyses, 
antecedent variables that were independently associated with the outcome (QOL: EORTC QLQ 
scores) and/or the mediators (uncertainty, PTSS), were included in the SEM model for testing 
mediation effects, based on the conceptual model in Figure 4.1. The initial model was then 
trimmed to obtain the final model (Figure 4.3) by subsequently deleting non-significant (p ≥ .05) 
paths until all the remaining variables had p < .05. In path analysis, if one level of a category 
variable was significant, all the levels of the categorical variable remained in the final model. 
Several fit indices were examined to assess the overall fit of the path model following the 
guideline for SEM (Bollen, 1989): The c2 test of model fit, the root mean square error of 
approximation (RMSEA), the standardized root mean square residual (SRMR), the Comparative 
Fit Index (CFI), and the Tucker-Lewis Index (TLI). Good fit is indicated by non-significant c2 
statistic, values of .95 or greater for the CFI and TLI, and .05 or smaller for RMSEA and SRMR 
(Browne & Cudeck, 1992; Hu & Bentler, 1999). Values between .05 and .08 for the RMSEA 






Of the 2,000 prospective participants who were mailed a survey, 173 (8.7%) packages 
were returned undeliverable and 35 (1.8%) individuals did not meet the inclusion criteria (no 
NMIBC by self-report, n = 6; unable to read and write a questionnaire by family report, n = 10; 
or deceased, n = 19). Of the 1,792 remaining survivors, 398 completed and returned their 
surveys, yielding a response rate of 22.2%. After excluding 22 participants who did not complete 
the measures of main outcomes (uncertainty, PTSS, and QOL), 376 participants were included in 
the initial analyses. We compared participants to non-participants using the available information 
from the North Carolina CCR and found that the participating survivors were more frequently 
white than non-participants (94.5% vs. 88.1%, p < .001). Other characteristics (sex, age, 
histology, stage at diagnosis, time since diagnosis) did not differ between participants and non-
participants. 
The characteristics of the participants are shown in Table 4.2. The majority was male 
(72.3%), non-Hispanic white (93.4%), married or living with partner (75.5%), and had more than 
a college education (73.2%). The mean age at study enrollment was 72.2 (SD = 9.2) and the 
mean years since diagnosis was 3.4 years (SD = 1.5). Transurethral resection of a bladder tumor 
(TURBT) was the primary treatment for 73.4% of the participants, intravesical immunotherapy 
for 43.4%, intravesical chemotherapy for 36.2%, and cystectomy for only 5.6%. NIMBC had 
recurred in 40.7% of the participants. Most of the participants (71.3%) had a positive smoking 
history (at least 100 cigarettes or 5 packs in entire life), and 10.6% were current smokers. More 
than two-thirds of the participants (255, 67.8%) had three or more comorbidities, with the most 
common comorbidities being high blood pressure (248, 66.0%), back pain (194, 51.6%), and 
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heart disease (157, 41.8%). Fifty-four participants (14.4%) had other cancers (e.g. prostate, n = 
16; skin cancer/melanoma/basal cell carcinoma, n = 9; GI cancer, n = 8; lung cancer, n = 6; etc.). 
Levels of Uncertainty, PTSS, and QOL 
Table 4.3 shows the levels of uncertainty, PTSS, and QOL. The average uncertainty score 
was 53.2 (SD = 12.0), with a range of 22-92, where higher scores indicated higher uncertainty. 
The average PCL-5 (PTSS) score was 7.1 (SD = 10.9) in a range of 0-66, where higher scores 
indicated more PTSS. Using the DSM-5 symptom cluster severity score, 5.3% of the participants 
met the provisional PTSD diagnosis (Table 4.4). Overall, 28.7% fulfilled the criteria for at least 
one PTSD symptom cluster. The average QOL global health status score and function score were 
73.6 (SD = 21.7) and 84.8 (SD = 18.5) respectively, where higher scores indicated better QOL 
(Table 4.3). The average QOL symptom score was 15.5 (SD = 17.2), where higher scores 
indicated lower QOL.  
Relationship between Uncertainty, PTSS, and QOL 
There were significant correlations between the uncertainty, PTSS, and all QOL domains 
(all p < .001) (Table 4.5). The uncertainty (MUIS-S) total score was inversely correlated with 
QOL global health status (r = -.40, p < .001) and QOL function (r = -.44, p < .001), and 
positively correlated with QOL symptoms (r = .42. p < .001). The total PTSS score (PCL-5) had 
inverse correlations with the QOL global health status (r = -.51, p < .001) and QOL function (r = 
-.74, p < .001), but positive correlations with QOL symptoms (r = .65, p < .001).  
Multiple Regression Analyses 
Table 4.6 displays the final results of the hierarchical regressions, showing the 
contribution of demographic, clinical, health/health behavior, and psychosocial variables that 
explain the variance in uncertainty (MUIS-S), PTSS (PCL-5), and QOL (EORTC QLQ-C30) 
scores. Among the demographic variables, sex, age at study enrollment, and income were 
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significantly associated with at least one of the outcomes listed above. Among the clinical 
variables, stage at diagnosis, receipt of intravesical immunotherapy, and being cured were 
significantly associated with at least one outcome. Among the health/health status variables and 
psychosocial variables, comorbidity number, social support, and cognition-ability were 
significantly associated with at least one outcome. Cognition-general concerns were significantly 
associated with all of the outcomes.  
The following variables were removed during the backward selection for all the outcomes 
because they were not significantly associated with uncertainty, PTSS, and QOL, and therefore 
are excluded from Table 4.8: education, marital status, insurance, receipt of cystectomy, receipt 
of intravesical chemotherapy, recurrence, time since diagnosis, general healthcare usage, and 
tobacco use. 
Uncertainty. Table 4.6 shows that uncertainty was significantly affected by sex, income, 
current disease status, cognition-abilities, and cognition-general concerns. After controlling for 
other model variables, significantly higher uncertainty was seen in participants who were male, 
had lower income, were not cured or did not know whether they were cured (vs. cured), had 
lower cognition-ability, and had higher cognition-general concerns. Uncertainty did not vary 
significantly by race/ethnicity, age at study enrollment, current treatment status, comorbidity 
number, or social support. 
PTSS. PTSS had significant associations with age at study enrollment, current disease 
status, comorbidity number, social support, and cognition-general concerns (Table 4.6). After 
controlling for other variables, significantly higher PTSS were seen in participants who were 
younger, were not cured or did not know whether they were cured (vs. cured), had more 
	
78	
comorbidities, had lower social support, and had higher cognition-general concerns. PTSS did 
not vary significantly by sex, race/ethnicity, receipt of TURBT, or cognition-ability.  
QOL: Global health status. We found sex, income, stage at diagnosis, receipt of 
intravesical immunotherapy, comorbidity number, social support, cognition-ability, and 
cognition-general concerns to be significantly associated with QOL global health (Table 4.6). 
Controlling for other model variables, significantly higher global health status was seen in 
participants who were female and had higher incomes. Cancer stage Tis had the lowest QOL 
global health status, whereas stages T1 and Ta had similar scores. Significantly lower QOL 
global health status was seen in participants who had not received intravesical immunotherapy, 
had more comorbidities, had lower social support, had lower cognition-ability, and had higher 
cognition-general concerns. QOL global health status did not vary significantly by race/ethnicity 
or age at study enrollment. 
QOL: Function. As seen in Table 4.6, current disease status, comorbidity number, social 
support, and cognition-general concerns were significant predictors of function. Current disease 
status was associated with function, with participants who did not know or were not cured having 
lower function than those who reported that they were cured. Step-down tests indicated that 
those who did not know if they were cured had significantly worse function than those who felt 
that they were cured (p > .01), and those who felt they were not cured did not have significantly 
worse function than those who felt they were cured (p = .08). Significantly lower function was 
seen in participants who had more comorbidities, lower social support, and higher cognition-
general concerns. After controlling for other covariates, function did not vary significantly by 
sex, race/ethnicity, age at study enrollment, employment, cystoscopy frequency, or whether the 
participant had an additional cancer.  
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QOL: Symptoms. We found receipt of intravesical immunotherapy, current disease 
status, comorbidity number, and cognition-general concerns to be significantly associated with 
symptoms (Table 4.6). After controlling for other model variables, significantly higher 
symptoms were seen in participants who had not received intravesical immunotherapy, were not 
cured or did not know whether they were cured (vs. cured), had more comorbidities, and had 
higher cognition-general concerns. However, symptoms did not vary significantly by sex, 
race/ethnicity, age at study enrollment, income, stage at diagnosis, or social support. 
Multiple regression assumptions. Multiple linear regression model assumptions 
(normality, homogeneous variance, linearity, and no multicollinearity) were examined in the 
regression analyses. There was no evidence of assumption violations in models for QOL global 
health status and uncertainty. Residual plots for models for QOL function, QOL symptoms, and 
PTSS showed potential minor heterogeneity of variance. The examination of the data indicated 
that this was likely to be due to a number of respondents clustered on the highest/lowest (i.e. 
excellent functioning, low symptoms, and low PTSS) value allowed by the scale. The usual 
approach to reduce heterogeneity of variance, namely transformation, would not address this 
clustering problem. Dichotomizing or categorizing the response was also not a good solution, 
because it would be inconsistent with the usual use of these well-established measures. We chose 
to leave the responses untransformed, with minor violations of the usual regression assumptions. 
SEM Analyses 
Measurement model. CFA was conducted for the observed variables derived from the 
QOL multidimensional scales to test the validity of measurement model and to determine 
whether the use of a single latent variable for QOL was appropriate before assessing the 
hypothesized structural model. The absolute values of the factor loadings ranged from .80 to .96, 
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and the R2 ranged from .64 to .93. All the factor loadings and R2 were statistically significant. 
These findings suggest a good fit in the model (Table 4.7).  
Path analysis model. Path analyses were conducted to examine the mediating effect of 
uncertainty and PTSS on the association between personal characteristics and QOL. After 
excluding those with missing personal characteristics variables, the SEM model included 296 
participants. The initial mediation model was built using personal characteristics variables with p 
< .20 in the multiple regression analyses. Then the model was trimmed to obtain the final model 
by subsequently deleting non-significant (p ≥ .05) paths until all the remaining variables had p 
< .05. Age at study enrollment, stage at diagnosis, receipt of TURBT in the past, and other 
cancer variables were removed from the model because they had no significant paths. In 
addition, levels of categorical variables that were not significantly different were combined to 
reduce the number of paths in the model: medium income (50,000 - 99,999) was combined with 
high income (≥ 100,000), employed with unemployed, and cystoscopy frequency – once per 4-6 
months with once per 7 months or longer. The goodness of fit statistics of the final model are 
presented in Table 4.8. The c2 of the final model is significant: 95.83 with df  = 49 and p < .001. 
The CFI ( .97), TLI (0.95), RMSEA ( .06), and SRMR ( .03) results indicate that the final model 
is a good fit to the data.  
Table 4.8 shows the effects (direct, indirect, and total effects) of the personal 
characteristic variables on QOL in the final path model (Figure 4.3). Among the personal 
characteristic variables, race/ethnicity and intravesical immunotherapy had a direct effect only, 
and the direction of these effects mirrored the regression findings. The other personal 
characteristic variables had direct and/or indirect effects on QOL by the way of uncertainty and 
PTSS. Being female and higher cognitive abilities were associated with lower uncertainty; and 
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while sex and cognitive abilities had no direct effect on PTSS or QOL, being female and higher 
cognitive abilities were associated with lower PTSS and higher QOL via the decrease in 
uncertainty. Low income was indirectly associated with lower QOL by the increase in 
uncertainty and PTSS. The participants who were not cured or who were uncertain about their 
cures had higher uncertainty and PTSS, and lower QOL than those who were cured; the effects 
on QOL were fully mediated by the increase in uncertainty and PTSS.  
Being currently in treatment, having more comorbidities, and having more cognitive 
general concerns had no effect on uncertainty, but were associated with higher PTSS and lower 
QOL via PTSS. Having more comorbidities and cognitive general concerns were also directly 
associated with lower QOL. Although being retired and having a higher frequency of 
cystoscopies had no effect on uncertainty, they were associated with lower PTSS and, indirectly 
through PTSS, with higher QOL. 
PTSS had a strong direct negative effect on QOL (-0.52).  Additionally, PTSS completely 
mediated the effect of uncertainty on QOL, where uncertainty had a direct positive effect on 
PTSS (0.38) and an indirect negative effect on QOL via the increase in PTSS (-0.20).  
Discussion 
To the best of our knowledge, this is the first study to measure the uncertainty and PTSS 
in NMIBC survivors. In this study, demographic and disease characteristics associated with 
uncertainty, PTSS, and QOL in NMIBC survivors were explored using multiple regression, and 
the relationships among uncertainty, PTSS, and QOL were examined using SEM techniques. We 
found the following: Firstly, NMIBC survivors experienced cancer-related uncertainty, and 
higher uncertainty were associated with male, lower income, lack of cure, lower cognition-
ability, and higher cognition-general concerns. Secondly, 28.7% of the participants had PTSS, 
and higher PTSS were associated with younger age, lack of cure, more comorbidities, less social 
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support, and higher cognition-general concerns. Lastly, uncertainty was negatively associated 
with QOL, and PTSS completely mediated the effect of uncertainty on QOL. 
The average cancer-related uncertainty score for NMIBC survivors in this study was 53.2 
(SD = 12.0, range 22-92, where a higher score indicated a greater level of uncertainty). This 
finding is similar to other studies on breast cancer survivors using the same instrument; 56.86 
(SD = 9.86) for older long-term (5-9 years post-treatment) breast cancer survivors and 56.65 (SD 
= 11.96) for younger mid-term (2-4 years post-treatment) breast cancer survivors (Clayton et al., 
2006; Hall, Mishel, & Germino, 2014). Our study suggests that cancer-related uncertainty is a 
salient experience for NMIBC survivors. The uncertainty in NMIBC survivors could be 
explained by their unique burdens of frequent recurrence/progression of NMIBC, repeated 
treatments, and lifelong surveillance.  
From the multiple regression analysis, we identified the factors associated with 
uncertainty. We found that males had higher uncertainty; however, the literature on the 
association between sex and uncertainty was limited (Ghodraty Jabloo et al., 2017). The 
association had been examined in only one previous study and no significant relationship 
between sex and uncertainty was reported in patients with colon cancer (Galloway & Graydon, 
1996), which is inconsistent with our finding. However, the study by Galloway & Graydon 
(1996) had methodological limitations, including a small sample size (male 20, female 20) and 
convenience sampling. Thus, the association of male sex with higher uncertainty should be 
confirmed by future studies. We found that higher uncertainty was associated with lower income, 
current disease status (not cured or did not know whether they were cured), lower cognition-
ability, and higher cognition-general concerns. The associations of uncertainty with income, 
current disease status, cognition-ability, and general concerns had not been studied in other 
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research, but these associations in our study were as expected in light of uncertainty in illness 
theory (Mishel, 1988, 1990).   
The prevalence of provisional PTSD diagnosis (using the symptom cluster method) in our 
NMIBC participants was 5.3%, which is somewhat lower than that found in some other cancer 
populations (from 7.3% to 13.8%), but higher than that of the general US adult population 
(3.5%) (Abbey et al., 2015). In addition, more than one in four (28.7%) NMIBC participants in 
our study reported PTSS (they met the PTSD diagnostic criteria for at least one PTSD symptom 
cluster), which is higher than the findings from other cancer studies and the general US adult 
population (10-20%) (Cordova et al., 2017). Although the prevalence should be cautiously 
compared with the findings of other studies, because different instruments were used, this 
finding suggests that NMIBC survivors might be experiencing PTSS more than the general 
population. Thus, healthcare providers should be mindful of this possibility when planning and 
delivering care. The assessment and management of PTSS are needed for NMIBC survivors in 
the survivorship phase of care.  
Our results from the multiple regression analysis show that younger age, lack of cure, 
more comorbidities, less social support, and more cognition-general concerns were 
independently associated with higher PTSS. The association of PTSS with age, comorbidity, and 
social support in this research is consistent with the literature on PTSS in other cancer survivors 
(Cordova et al., 2017; S. K. Smith, Zimmerman, Williams, Preisser, & Clipp, 2008; Swartzman, 
Booth, Munro, & Sani, 2017). Older participants had significantly less PTSS; this could be 
explained by the fact that older survivors may have more experience in dealing with life-
threatening events than younger survivors, be more resilient, or have other protective 
psychological factors.  
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The exploratory path model (Figure 4.1) tested the relationships between personal 
characteristics, uncertainty, PTSS, and QOL. Our findings indicated that uncertainty and PTSS 
helped to explain the relationships between personal characteristics (demographic and disease 
characteristics) and QOL. The QOL model we tested explained a large amount of the variance 
(72%) with many key personal characteristics, uncertainty, and PTSS. Our findings that 
uncertainty was significantly and negatively associated with QOL are in agreement with previous 
studies of patients with other cancers (breast, renal, and prostate) (Parker et al., 2013, 2016, 
Sammarco, 2003, 2009; Wallace, 2003). In this study, PTSS completely mediated the effect of 
uncertainty on QOL. The relationship between uncertainty and PTSS has been documented in 
childhood cancer survivors (Lee, Gau, Hsu, & Chang, 2009) but, to the best of our knowledge, 
this is the first time this relationship is described in relation to NMIBC survivors. In addition, we 
found that higher PTSS had a strong association with poorer QOL, which is consistent with the 
literature (Geffen et al., 2003; Shand, Brooker, Burney, Fletcher, & Ricciardelli, 2015; S. K. 
Smith et al., 2011).  
Comorbidities (total effect = -0.34, the sum of a direct and indirect effect; with an 
increase in comorbidities by 1 SD, QOL declined by 0.34 SD), cognition-general concerns (total 
effect = -0.48), uncertainty (total effect = -0.20), and PTSS (total effect = -0.52) had strong 
negative effects on QOL. A survivor with more comorbidities, more cognitive concerns, more 
uncertainty, and more PTSS had a lower QOL. In addition, the effects of comorbidities and 
cognition-general concerns on QOL were partially mediated by PTSS. Previous researchers have 
reported that comorbidities have a significant negative impact on QOL in cancer survivors (Fung 
et al., 2014; Pisu et al., 2017; A. W. Smith et al., 2008). Accordingly, to improve the QOL of 
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NMIBC survivors, adequate assessment and management of comorbidities are necessary and 
should be included in the care of cancer survivors.  
Limitations and Strengths 
Our study provides insight into the QOL of NMIBC survivors, and there are some 
limitations to consider. Firstly, this was a cross-sectional study; therefore, definitive inferences 
cannot be made about the directions of causal relationships among uncertainty, PTSS, and QOL. 
However, the findings of this study were supported by the literature about the effects of 
uncertainty and PTSS on QOL, and the interpretation of the findings were guided by a theoretical 
model. Nonetheless, further longitudinal investigation would establish the causal relationship. 
Secondly, the sample was mostly non-Hispanic white (93.4%), which limited the generalizability 
of the findings to other racial/ethnic groups. Further validation of the relationships between 
personal characteristics, uncertainty, PTSS, and QOL in other racial/ethnic populations is 
needed. Lastly, PTSS were assessed using self-report questionnaires only. Although the 
questionnaire (PCL-5) is a validated instrument, it may not be as accurate as clinician-
administered structured diagnostic interviews for PTSD. In addition, current disease status (cured 
or not), treatment, and surveillance information were collected by self-report questionnaires only, 
which may not be as accurate as data from clinical records.  
The significant strength of this study lies in the development of a conceptual model that 
incorporates personal characteristics (demographics, disease/health status), uncertainty, PTSS, 
and QOL factors and the identification of the theoretically meaningful relationships among the 
factors. An additional strength of this study is the use of a population-based random sample of 
NMIBC survivors in North Carolina.  
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Implications for Practice 
The findings of this study suggest that psychosocial assessment and management are 
essential to improving the QOL in NMIBC survivors. An important aspect of this study is that 
we measured two psychosocial factors (uncertainty and PTSS) that can be modified through 
coping strategies and established interventions. According to Mishel’s uncertainty in illness 
theory, appropriate education, social support, and support from healthcare providers can reduce 
uncertainty by helping survivors predict and understand their illness experience accurately 
(Mishel, 1988, 1990). Common strategies for uncertainty management include obtaining 
knowledge regarding cancer and health, cancer-related limitations, and possible events in the 
future (Jonsson, Aus, & Berterö, 2010). PTSD treatments have been studied in patients with 
cancer, and have shown utility in the cancer population. Evidence-based psychotherapeutic 
PTSD treatments that have been studied in patients with cancer include cognitive behavioral 
therapy (CBT) interventions (DuHamel et al., 2010; Kangas, Milross, Taylor, & Bryant, 2013), 
eye movement desensitization and reprocessing (EMDR) intervention (Jarero et al., 2015), and 
mindfulness (Bränström, Kvillemo, Brandberg, & Moskowitz, 2010). Healthcare providers are in 
critical positions to support NMIBC survivors. Thus, healthcare providers should monitor 
survivors’ physical and psychosocial health (fear of uncertainty, PTSS, and QOL) at every clinic 
visit. Providing appropriate support through referrals and cancer support services may help 
reduce uncertainty and PTSS, ultimately improving their QOL.  
Conclusion 
The current study demonstrated the prevalence of uncertainty and PTSS in NMIBC 
survivors and tested the theoretical model: relationships of uncertainty, PTSS and QOL. The 
findings of this study showed that uncertainty and PTSS were significantly and inversely 
associated with QOL in NMIBC survivors. In addition, several covariates were identified that 
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either directly or indirectly, through uncertainty and/or PTSS, relate to QOL. The findings from 
this study will advance understanding about factors related to uncertainty, PTSS, and QOL. 




Table 4.1. Personal Characteristics Used As Independent Variables in Multiple Regression 
Category Variable 
Demographics Sex, race/ethnicity, age at study enrollment, income, education, 
marital, employment, insurance 
Disease Characteristics Stage at diagnosis, treatment type (TURBT, cystectomy, 
intravesical chemotherapy, intravesical immunotherapy), current 
treatment status, current disease status, recurrence, frequency of 
surveillance cystoscopy, time since diagnosis 
Health/Health-behavior 
status 
Other cancer, comorbidities, general healthcare usage, tobacco use 





Table 4.2. Participants Characteristics 
Characteristic Participants (n=376) 
Sex† 
  Male 










Age at diagnosis, years† 
Mean (SD), Range 
 
68.3 (9.2), 34-89 
Age at study enrollment, years† 
Mean (SD), Range 
 
72.2 (9.2), 39-94 











≤ High school graduate 
Some college or technical school/College graduate 
Post-graduate 






Marital status  
Married/ Living with partner 
Never married/ Divorced/ Widowed/ Separated 















Current health care coverage 
Don’t have 
Private insurance 
Government health care coverage (Medicare, Medicaid) 














All types of previous treatment  
TURBT 
Intravesical immunotherapy  
Intravesical chemotherapy  
Removal of bladder 
Radiation therapy 
Other 













Characteristic Participants (n=376) 
Years since diagnosis† 
Mean (SD), Range 
 
3.4 (1.5), 1-6 
Current treatment status 
Not in treatment 
Receiving treatment 

























Current cystoscopy frequency 
   Per 0-3 months 
Per 4-6 months 
Per 7-11 months 
Per 1 year 
Per 2 years 
Only had once 









Number of comorbidity  
 Mean (SD), Range 
 
0 












New other cancers 
Yes  
No 





Visit a primary care provider for general health needs within past 















Smoking history (at least 100 cigarettes (5 packs) in entire life) 
Yes 
No 












No response given 
 
40 (10.6%)   
329 (87.5%) 
7 (1.9%) 




Table 4.3. Mean Scores, Possible and Actual Score Ranges for Instruments 
Measure Characteristic Possible 
Range 
n Mean (SD) Range 
MUIS-S Uncertainty† 22 – 110  376 53.2 (12.0) 22 – 92 
PCL-5 PTSS total† 0 – 80 376 7.1 (10.9) 0 - 66 
Intrusions (Q1-5) † 0 – 20 376 1.6 (3.0) 0 - 15 
Avoidance (Q6-7) † 0 – 8 375 0.6 (2.3) 0 - 8 
Negative alterations in cognitions 
and mood (Q8-14) † 
0 – 28 376 2.2 (4.2) 0 - 25 
Alterations in arousal and reactivity  
(Q15-20) † 
0 – 24 376 2.6 (3.8) 0 - 23 
EORTC  
QLQ-C30 
Global health status 0 – 100 364 73.6 (21.7) 0 - 100 
Function 0 – 100 376 84.8 (18. 5) 4.4 - 100 
Symptom† 0 – 100 376 15.5 (17.2) 0 - 89.7 
PROMIS Cognition - Abilities 8 – 40 372 31.9 (8.5) 8 - 40 




Social support  19-95 369 77.5 (19.4) 19 - 95 




Table 4.4. PTSD 
 Frequency 
PCL-5 total scorea ³ 33 17 (4.5%) 
< 33 359 (95.5%) 
PTSD symptom clustersb 0 268 (71.3%) 
1 48 (12.8%) 
2 23 (6.1%) 
3 17 (4.5%) 
4 20 (5.3%) 
Provisional PTSD diagnosisc Yes 20 (5.3%) 
No 356 (94.7%) 
aPCL-5 total score ³ 33 is a cut-point for provisional diagnosis of PTSD.  
bPTSD symptom clusters: Each item rated ³ 2 (moderately) was endorsed as a symptom, then at 
least 1 intrusion item (questions 1-5), 1 avoidance item (questions 6-7), 2 negative alterations in 
cognitions and mood items (questions 8-14), and 2 alterations in arousal and reactivity items 
(questions 15-20) are required for each symptom cluster. 
cProvisional PTSD diagnosis: Each item rated ³ 2 (moderately) was endorsed as a symptom, then 
PTSD diagnosis requires at least 1 intrusion item (questions 1-5), 1 avoidance item (questions 6-
7), 2 negative alterations in cognitions and mood items (questions 8-14), and 2 alterations in 







Table 4.5. Matrix of Pearson Correlation Coefficients  




















MUIS Uncertainty 1.00          
PCL PTSD total  .55*** 1.00          
Intrusion (B)  .51***  .85*** 1.00        
Avoidance (C)  .40***  .77***  .69*** 1.00       
Negative alterations in 
cognitions and mood (D) 
 .49***  .94***  .72***  .67*** 1.00      
Alterations in arousal 
and reactivity (E) 
 .49***  .90***  .64***  .58***  .81*** 1.00     
Provisional PTSD Dx  .35***  .74***  .62***  .64***  .72***  .63*** 1.00    
EORTC 
QLQ- C30 
Global health status -.40*** -.51*** -.38*** -.27*** -.52*** -.51*** -.34*** 1.00    
Functional scales -.44*** -.74*** -.54*** -.50*** -.72*** -.74*** -.48*** .75*** 1.00  




Urinary symptoms   .39***  .51***  .41***  .33***  .46***  .51***  .33*** -.48*** -.57***  .58*** 
Malaise  .37***  .56***  .45***  .29***  .54***  .55***  .44*** -.54*** -.58***  .62*** 
Future worries   .50***  .70***  .68***  .57***  .63***  .58***  .44*** -.44*** -.60***  .59*** 
Bloating and flatulence   .32***  .48***  .38***  .30***  .46***  .48***  .31*** -.46*** -.55***  .62*** 
Sexual function  -.14** -.09 -.05 -.04 -.08 -.11* -.01  .19***  .14** -.13* 
Intravesical treatment 
issues 
 .32***  .51***  .43***  .37***  .48***  .48***  .43*** -.37*** -.48***  .48*** 
Sexual intimacy  .21***  .30***  .17*  .22***  .33***  .30***  .18*** -.31*** -.35***  .29*** 
Risk of contaminating 
partner 
 .18***  .22***  .23***  .22***  .21***  .16**  .13* -.15* -.19***  .18*** 
Sexual enjoyment -.11* -.10 -.09 -.09 -.10 -.08 -.06  .16**  .14* -.09 
Male sexual problems  .09  .18**  .06  .07  .20**  .23***  .07 -.29*** -.33***  .28*** 
Female sexual problems  .04  .03 -.06  .06  .05  .05 -.02  .004  .05  .01 
PROMIS Cognition-abilities -.44*** -.46*** -.35*** -.32*** -.43*** -.46*** -.35***  .53***  .53*** -.47*** 
Cognition- 
general concerns 

























MOS Social support -0.28*** -0.31*** -0.22*** -0.24*** -0.31*** -0.29*** -0.21*** 0.31*** 0.32*** -0.29*** 
Note. Dx = Diagnosis. 







Table 4.6. Multiple Regression for Uncertainty, PTSS, and Quality of Life 
 Quality of life Uncertainty PTSS 
 Global health 
status 
Function Symptom   
Variable Β (SE) Β (SE) Β (SE) Β (SE) Β (SE) 
Demographics 
Sex  Female 5.4 (2.1)** 0.6 (1.6) 0.7 (1.6) -3.5 (1.3)** -1.3 (1.0) 
Male Ref Ref Ref Ref Ref 
Race/ethnicity   Non-Hispanic white -7.3 (3.8) -5.3 (3.2) 4.6 (2.9) -3.5 (2.3) -0.6 (2.0) 
Other/Unknown Ref Ref Ref Ref Ref 
Age at study enrollment  0.1 (0.1) 0.1 (0.1) -0.1 (0.1) -0.01 (0.06) -0.2 (0.1)** 
Income <50,000 -7.2 (2.6)* - 3.5 (2.0) 3.9 (1.6)** - 
50,000-99,999 -3.2 (2.5) 0.6 (1.9) -0.3 (1.5)  
≥100,000 Ref Ref Ref  
Employment  Employed - 7.5 (3.8) - - - 
Retired  6.6 (3.6)   
Unemployed  Ref   
Disease Characteristics 
Stage at diagnosis T1 -0.5 (2.1)* - 2.8 (1.6) - - 
Tis -10.7 (3.7) 4.3 (2.9) 
Ta Ref Ref 




No -7.4 (1.8)*** - 4.6 (1.4)** - - 
Yes Ref Ref 
Current treatment status No - - - 2.6 (1.6) - 
Yes Ref 
Current disease status: Cure Don’t know - -5.8 (1.8)** 3.9 (1.7)* 7.6 (1.4)*** 4.4 (1.1)*** 
No -4.5 (2.5) 5.8 (2.5) 8.6 (2.2) 6.6 (1.6) 







Note. Ref = reference group. 
*p < .05; **p < .01; ***p < .001 for overall test of association between variable and outcome. 
	
   Quality of life  Uncertainty PTSS 
  Global health 
status 
Function Symptom   
Variable  Β (SE) Β (SE) Β (SE) Β (SE) Β (SE) 
Cystoscopy frequency Once per 0-3 months - 2.5 (2.0) - - - 
Once per 4-6 months -1.3 (1.9) 
Once per 7 months or longer Ref 
Health/Health-behavior status      
Other cancer No - -3.6 (2.1) - -  
Yes  Ref    
Comorbidity number - -2.9 (0.4)*** -2.8 (0.3)*** 2.8 (0.3)*** 0.4 (0.3) 1.0 (0.2)*** 
Psychosocial factor       
Social support   0.1 (0.1)**  0.1 (0.04)*** -0.1 (0.04) -0.04 (0.03) -0.1 (0.03)* 
Cognition: Abilities   0.5 (0.2)**  -  - -0.3 (0.1)*** -0.1 (0.1) 





Table 4.7. Measurement Model Using Confirmatory Factor Analysis, Standardized Coefficients (N=296) 
Latent Variable and 
Measures 
Mean (SD) Factor Loadings R2 
Quality of Life     
Global Health Status 73.8 (21.5) .80*** .64*** 
Function 84.8 (18.5) .96*** .93*** 
Symptom 15.0 (16.9) -.92*** .84*** 


















Table 4.8. Decomposition of Effects of the Final Model, Standardized Coefficients (N=296) 
Predictor variables Uncertainty  PTSS  QOL 
 
Direct  Direct Indirect via 
uncertainty 








Demographics            
Sex: Female  -0.13**  - -0.05* -0.05*  - - 0.03* 0.03* 0.03* 
Non-Hispanic White -  - - -  -0.08* - - - -0.08* 
Low income (<$50,000) 0.15**  - 0.06** 0.06**  - - -0.03** -0.03** -0.03** 
Retired -  -0.15** - -0.15**  - 0.08** - 0.08** 0.08** 
Disease Factors            
Currently in treatment -  0.12* - 0.12*  - -0.06* - -0.06* -0.06* 
Intravesical 
immunotherapy 
-  - - -  0.10** - - - 0.10** 
Cure: Not cured 0.17**  0.10* 0.06** 0.16**  - -0.05* -0.03** -0.08** -0.08** 
Cure: Don’t know 0.26**  0.06 0.10** 0.16**  - -0.03 -0.05** -0.08** -0.08** 
Cystoscopy frequency: 
Every 0-3 month 
-  -0.09* - -0.09*  - 0.05* - 0.05* 0.05* 
Health status            
Comorbidities -  0.15** - 0.15**  -0.26** -0.08** - -0.08** -0.34** 
Psychosocial factor            
Cognition-abilities -0.39**  - -0.15** -0.15**  - - 0.08** 0.08** 0.08** 
Cognition-general 
concerns 
-  0.34** - 0.34**  -0.30** -0.18** - -0.18** -0.48** 
Psychological effects            
Uncertainty N/A  0.38** N/A 0.38**  - -0.20** - -0.20** -0.20** 
PTSS N/A  N/A N/A N/A  -0.52** N/A N/A N/A -0.52** 
R2 .33**  .49**  0.72** 
Model fit χ2 (df) = 95.83 (49), p-value < .001; RMSEA = .06; SRMR = .03; CFI = .97; TLI = 0.95 
Note. N/A = not applicable. 






Figure 4.1. The conceptual model of QOL among NMIBC survivors [adapted from Smith 



































Figure 4.2. Hypothesized mediation model: Reduced for SEM [the original conceptual 
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CHAPTER 5: FINDINGS AND IMPLICATIONS 
Introduction 
There are more than 696,000 people living with bladder cancer in the United States (US) 
(National Cancer Institute, 2018). Of the 79,000 people who were diagnosed with bladder cancer 
in 2017, approximately 75% had non-muscle-invasive bladder cancer (NMIBC) (National 
Cancer Institute, 2018; Sanchez & Wszolek, 2015). Despite the fact that the majority of newly-
diagnosed bladder cancers is NMIBC, research focusing on the survivorship experience in 
bladder cancer patients has been predominantly among the minority population, namely those 
with muscle-invasive disease (Mohamed et al., 2016). NMIBC survivors have unique burdens 
associated with their diagnosis, frequent recurrence/progression, repeated treatments, and 
lifelong surveillance (Babjuk et al., 2017; Sylvester et al., 2006).  
The overarching purpose of this dissertation was to address the gaps in knowledge related 
to quality of life (QOL) of NMIBC survivors. The specific aims of the research were to: 1) 
examine the prevalence of uncertainty, post-traumatic stress disorder symptoms (PTSS), and 
QOL among NMIBC survivors; 2) identify factors associated with uncertainty, PTSS, and QOL; 
and 3) explore the relationships among uncertainty, PTSS, and QOL. This dissertation included 
one systematic review and two independent analyses of survey data collected from a sample of 
NMIBC survivors in North Carolina that were focused on QOL, uncertainty, PTSS, and 
associated factors in NMIBC survivors. In this chapter, the findings of each study (chapters 2-4) 
are reviewed and the strengths and limitations of the dissertation study are presented, along with 
the implications for research and practice. 
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Findings of Dissertation 
First Manuscript (Chapter 2): “Quality of Life in Non-Muscle-Invasive Bladder Cancer 
Survivors: A Systematic Review” 
This manuscript was a review of the literature exploring QOL in NMIBC survivors. 
While the focus of the review was on NMIBC, some of the studies included information on 
muscle-invasive bladder cancer (MIBC). The review was based on an analysis of 14 quantitative 
and one mixed-method studies. The review showed that bladder cancer survivors had poorer 
QOL in all domains of function and symptoms than the general population. Among the bladder 
cancer survivors, the cystectomy group had worse QOL than the intact bladder group. However, 
among the long-term (mean time since diagnosis 99.8 months) bladder cancer survivors, QOL 
did not differ between the cystectomy and the intact bladder groups. Additionally, the findings 
showed that burdens of repeated transurethral resection of a bladder tumor (TURBT), 
intravesical instillation treatment, and surveillance procedures were associated with urinary and 
bowel problems, decreased mental health, and impaired sexual function among NMIBC 
survivors.  
Second Manuscript (Chapter 3): “Quality of Life among Non-Muscle-Invasive Bladder 
Cancer Survivors: A Population-Based Study” 
This manuscript was a report of findings from a population-based survey study in North 
Carolina, the aim of which was to examine the QOL of NMIBC survivors. The analysis was of 
data from 376 NMIBC survivors. The main findings of this study were that NMIBC survivors 
had urinary and bowel symptoms, sexual problems, and future worries. These were noted across 
the survivorship continuum, regardless of time from diagnosis. Only sexual function improved 
over time since diagnosis. Additionally, global health status, functions (physical, role, social), 
and financial difficulties differed by cancer stage at diagnosis; and sexual QOL differed by sex 
and type of treatment. The stages for NMIBC are Ta (found on a small section of tissue that 
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easily can be removed with TURBT), Tis (found on the surface of the bladder, which often 
recurs after treatment), and T1 (tumor has spread to the subepithelial connective tissue but does 
not involve the bladder wall muscle). Lower stage (Ta) was associated with better QOL in 
several domains, including global health status, physical functioning, role functioning, social 
functioning, fatigue, dyspnea, and financial difficulties. Stages Ta and T1 had less intravesical 
treatment issues than stage Tis. Male survivors had better sexual function and enjoyment than 
females, but also higher discomfort with sexual intimacy and more concerns about contaminating 
their partners. The cystectomy group had worse sexual function, more discomfort with sexual 
intimacy, lower sexual enjoyment, and more male sexual problems than the non-cystectomy 
group. 
Third Manuscript (Chapter 4): “Relationships among Uncertainty, Post-Traumatic Stress 
Disorder Symptoms, and Quality of Life in Non-Muscle-Invasive Bladder Cancer 
Survivors” 
This manuscript was a description of the findings of a study, the aim of which was 1) to 
examine uncertainty, PTSS, and QOL in NMIBC survivors; 2) to identify factors associated with 
uncertainty, PTSS, and QOL; and 3) to explore the relationships among uncertainty, PTSS, and 
QOL. Multiple regression and structural equation modeling were used for analysis. The findings 
of the analyses indicate notable burdens of cancer-related uncertainty in NMIBC survivors. 
Moreover, male, lower income, lack of cure, lower cognition-ability, and higher cognition-
general concerns were associated with higher uncertainty. In addition, the prevalence of PTSS 
(28.7%) and PTSD (5.3%) were higher than in the general US adult population (PTSS 10-20%, 
PTSD 3.5%). Higher PTSS were associated with younger age, lack of cure, more comorbidities, 
less social support, and more cognition-general concerns. 
The main findings of this study were that uncertainty was significantly and negatively 
associated with QOL; and PTSS completely mediated the effect of uncertainty on QOL. 
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Additionally, survivors with more comorbidities, higher cognition-general concerns, higher 
uncertainty, and more PTSS had a significantly lower QOL. 
Strengths and Limitations of Dissertation 
This dissertation has several strengths. Firstly, it comprises a population-based study in 
which a random sampling method was used. The study sample was randomly drawn from the 
NMIBC population in North Carolina through the central cancer registry. Secondly, to the best of 
our knowledge, this is the first study in which uncertainty and PTSS, which are associated with 
QOL, were measured in NMIBC survivors. Compared with previous studies that described QOL 
in NMIBC (Schmidt et al., 2015; Singer et al., 2013; Wei, Li, Liang, & Jianbo, 2014; Yoshimura 
et al., 2005), this study went further by examining psychosocial factors associated with QOL. 
Importantly, uncertainty and PTSS are psychosocial factors that can be modified through 
established interventions to support coping strategies. Thirdly, the conceptual model for the SEM 
analysis was based on a solid theoretical foundation, incorporating the Stress, Appraisal, and 
Coping Theory (Folkman, Lazarus, Gruen, & DeLongis, 1986) and the Uncertainty in Illness 
Theory (Mishel, 1988). The findings of this analysis demonstrated that uncertainty is negatively 
associated with QOL, and that PTSS completely mediates the effect of uncertainty on QOL in 
NMIBC population.  
Despite its strengths, this dissertation has some limitations that are worth noting. Firstly, 
as the study was a cross-sectional design, we did not capture information about changes over 
time. Thus, we are not able to infer longitudinal changes in QOL. Further research using a 
longitudinal design is needed to provide better information about QOL changes over time. 
Secondly, although a random sample was contacted, the participants were disproportionately 
white compared to the non-participants (94.5% vs. 88.1%). Although bladder cancer is more 
common in Caucasians, further research in minority NMIBC survivors is needed to confirm the 
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generalizability of the findings to diverse populations. Thirdly, current disease status (cured or 
not), treatment, surveillance information, and PTSS were assessed by self-report. The disease-
related information collected by self-report may not be as accurate as data from medical records. 
Also, PTSS can be assessed more accurately by clinician-administered structured diagnostic 
interviews. 
Implications 
Implications for Research 
The findings of this study indicate several areas for future research. Firstly, although we 
determined that coexisting comorbidities, uncertainty, and PTSS had strong effects on QOL 
among NMIBC survivors, the longitudinal effects of those on QOL have not been investigated in 
this population. In the future, more studies using longitudinal design are necessary to examine 
the effects of comorbidities, uncertainty, and PTSS on QOL over time. Secondly, the effects of 
financial burdens of NMIBC care on QOL should be addressed in future studies. Bladder cancer 
carries the most expensive lifetime treatment cost per-patient among all cancers. With increasing 
recognition of the financial burdens of cancer care in general (Ubel, Abernethy, & Zafar, 2013), 
the paucity of related work in the NMIBC population warrants additional study. Thirdly, further 
studies to develop and validate bladder cancer-specific QOL instruments are needed. Among the 
bladder cancer-specific QOL instruments, only the bladder cancer index (BCI) and Functional 
Assessment of Cancer Therapy-Vanderbilt Cystectomy Index (FACT-VCI) have been validated 
to date (Mohamed et al., 2016). There is only one NMIBC-specific QOL instrument, EORTC 
QLQ-NMIBC24, and validation studies of the instrument are still ongoing. Hence, the ongoing 
development and validation of bladder cancer-specific QOL instruments warrant further support 
and research to improve the quality of evidence about QOL in patients with NMIBC. 
	
	 113	
Implications for Practice 
The findings of this dissertation have several practical implications. Firstly, ongoing 
symptom assessment and screening are important to improve the QOL of NMIBC survivors, who 
experience lower physical, psychological, and social QOL compared to the general population. 
Oncology healthcare providers, who are in a critical position for assessing and managing 
symptoms and concerns, should assess symptoms and survivorship issues regularly to provide 
personalized resources. Secondly, as NMIBC treatment and surveillance cystoscopies are 
associated with physical and psychological symptoms, oncology nurses need to educate NMIBC 
survivors about potential health impairments and symptom management strategies. This could be 
undertaken by providing informational sessions and/or other educational approaches. By 
supporting NMIBC survivors, nurses can contribute to their adherence to the NMIBC treatment 
and surveillance follow-up schedule, which is essential for extended cancer survival. Thirdly, 
psychosocial assessment and management are important to reduce uncertainty and PTSS, and to 
improve the QOL of NMIBC survivors. The finding from SEM analysis of this dissertation 
showed that psychosocial factors (uncertainty and PTSS) had significant negative effects on 
QOL. Uncertainty and PTSS can be modified through coping strategies and established 
interventions. Uncertainty can be reduced by appropriate education, social support, and support 
from healthcare providers helping survivors to predict and understand their illness experience 
accurately (Mishel, 1988, 1990). Evidence-based psychotherapeutic PTSD treatments, which 
have been studied in cancer patients, include cognitive behavioral therapy (CBT) interventions 
(DuHamel et al., 2010; Kangas, Milross, Taylor, & Bryant, 2013), eye movement desensitization 
and reprocessing (EMDR) intervention (Jarero et al., 2015), and mindfulness (Bränström, 




This study showed the impact of NMIBC diagnosis, treatment, and surveillance on QOL 
among NMIBC survivors. The results of this dissertation suggest that uncertainty and PTSS were 
significantly and inversely associated with the QOL of NMIBC survivors. The QOL path model 
in this dissertation highlighted the need for the assessment and management of uncertainty and 
PTSS in this population. Therefore, clinicians, nurses, and researchers should recognize the 
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